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Abstract The Rotterdam Study is a prospective cohort
study ongoing since 1990 in the city of Rotterdam in The
Netherlands. The study targets cardiovascular, endocrine,
hepatic, neurological, ophthalmic, psychiatric, dermato-
logical, oncological, and respiratory diseases. As of 2008,
14,926 subjects aged 45 years or over comprise the Rot-
terdam Study cohort. The findings of the Rotterdam
Study have been presented in over a 1,000 research
articles and reports (see www.erasmus-epidemiology.nl/
rotterdamstudy). This article gives the rationale of the
study and its design. It also presents a summary of the
major findings and an update of the objectives and
methods.
Keywords Cardiovascular diseases  Cohort study 
Dermatological diseases  Endocrine diseases 
Epidemiologic methods  Genetic epidemiology 
Liver diseases  Neurological diseases  Ophthalmic
diseases  Otolaryngological diseases 
Pharmacoepidemiology  Psychiatric diseases 
Respiratory diseases
Introduction
The Rotterdam Study was designed in the mid-1980s as a
response to the demographic changes that were leading to
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an increase of the proportion of elderly people in most
populations [1]. It was clear that this would produce a
strong rise in elderly people living with diseases, as most
diseases cluster at the end of life, and that to discover the
causes of diseases in the elderly one would have to study
risk factors of those diseases [2]. A major approach to
finding causes is the prospective follow-up study, which
has proven quite effective in finding causes of heart disease
and cancer.
The design of the Rotterdam Study
The design of the Rotterdam study is that of a prospective
cohort study among, initially, 7,983 persons living in the
well-defined Ommoord district in the city of Rotterdam in
The Netherlands (78 % of 10,215 invitees). They were all
55 years of age or over and the oldest participant at the
start was 106 years [3]. The study started with a pilot phase
in the second half of 1989. From January 1990 onwards
participants were recruited for the Rotterdam Study. Fig-
ure 1 gives a diagram of the various cycles in the study. In
2000, 3,011 participants (out of 4,472 invitees) who had
become 55 years of age or moved into the study district
since the start of the study were added to the cohort. In
2006 a further extension of the cohort was initiated in
which 3,932 subjects were included, aged 45–54 years, out
of 6,057 invited, living in the Ommoord district. By the end
of 2008, the Rotterdam Study therefore comprised 14,926
subjects aged 45 years or over [4–6]. The overall response
figure for all three cycles at baseline was 72.0 % (14,926 of
20,744).
The participants were all examined in some detail at
baseline. They were interviewed at home (2 h) and then
had an extensive set of examinations (a total of 5 h) in a
specially built research facility in the centre of their dis-
trict. These examinations focussed on possible causes of
invalidating diseases in the elderly in a clinically state-of-
the-art manner, as far as the circumstances allowed. The
emphasis was put on imaging (of heart, blood vessels, eyes,
skeleton and later brain) and on collecting body fluids that
enabled further in-depth molecular and genetic analyses.
These examinations were repeated every 3–4 years in
characteristics that could change over time. And so there
were examination cycles from 1990 to 1993, from 1993 to
1995, from 1997 to 1999, from 2000 to 2001, from 2002 to
2004, from 2004 to 2005, from 2006 to 2008, from 2009 to
2011, from 2011 to 2012, and from 2012 onwards (Fig. 1).
In December 2013 the second examination cycle for the
third cohort (RS-III-2) will be finished.
The participants in the Rotterdam Study are followed for
a variety of diseases that are frequent in the elderly (and
many are also in the not so elderly): coronary heart disease,
heart failure and stroke, Parkinson disease, Alzheimer
disease and other dementias, depression and anxiety dis-
orders, macular degeneration and glaucoma, respiratory
diseases, liver diseases, diabetes mellitus, osteoporosis,
dermatological diseases and cancer.
The Rotterdam Study has been approved by the insti-
tutional review board (Medical Ethics Committee) of the
Erasmus Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare and Sports. The
approval has been renewed every 5 years, as well as with
the introduction of major new elements in the study (e.g.,
MRI investigations).
In the remainder of this article the objectives and major
findings will be presented with an update of the research
methods for cardiovascular diseases, dermatological dis-
eases, endocrine diseases, liver diseases, neurological dis-
eases, ophthalmic diseases, psychiatric diseases,
respiratory diseases, as well as for genetic and biomarker
studies and for pharmaco-epidemiologic studies. For rele-
vant recent EJE references see [7–19].
Cardiovascular diseases
Objectives
Research on the epidemiology of cardiovascular disease
focuses on the etiology, prognosis, and prediction of car-
diovascular disorders (including coronary heart disease,
stroke, heart failure) diabetes mellitus and metabolic syn-
drome. The main emphasis is on prevention and manage-
ment of a first cardiovascular event but prevention of
secondary events is also an area of interest. Putative risk
factors include five groups: lifestyle factors, endocrine
factors, factors involved in hemostasis, inflammation and
endothelial function, metabolomic factors and genetic
factors. We have five specific focused themes:
1. Lifestyle: focused on evaluating the role of lifestyle
factors (including nutrition, physical activity, sleep and
smoking) in maintaining cardiovascular health as well
as the interactions that lifestyle factors might have
other factors (e.g. genes and medications).
2. Biomarkers and genes: aimed to identify relevant
biomarkers for the identification of novel mechanisms
of disease. These incorporate both molecular and
genetic factors together with their potential interac-
tions. Genomics and metabolomics play a key role.
3. Prediction and women’s cardiovascular health: aimed
to improve the identification of individuals at increased
risk of developing cardiovascular disease in order to
point out windows of opportunities that could permit
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early preventive interventions and personalised care. A
special focus is given to evaluating specific factors and
formulating targeted strategies to prevent cardiovas-
cular disease in women.
4. High risk: focused on predictors and prognosis of
chronic cardiovascular conditions, like heart failure,
pulmonary hypertension, and atrial fibrillation.
5. Imaging: this work theme aims to identify the contribu-
tion that new technologies can provide to the maximum
benefit of early diagnosis and accurate prognostication.
Major focus is on non-invasive assessment of athero-
sclerosis to improve the understanding of the athero-
sclerotic process and the prediction of cardiovascular
disease, including measurement of coronary calcifica-
tion with electron-beam and multi-detector CT (MDCT)
and carotid plaque characterization by MRI.
Major findings
Recognized and unrecognized myocardial infarction
We found that a high proportion of incident myocardial
infarctions remains clinically unrecognized. The incidence
rate of recognized myocardial infarction in the Rotterdam
Study was 5.0 per 1,000 person years. The incidence was
higher in men (8.4) than in women (3.1). The incidence
rate of unrecognized infarction was 3.8 per 1,000 person
years. Men (4.2) and women (3.6) had approximately
similar incidence. Hence, the proportion of unrecognized
infarction is lower in men (33 %) than in women (54 %)
[20]. We have further identified a two-fold increased risk in
developing heart failure or atrial fibrillation among men
with unrecognized myocardial infarction [21, 22].
Fig. 1 Diagram of examination cycles of the Rotterdam Study (RS).
RS-I-1 refers to the baseline examination of the original cohort (pilot
phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-
2, RS-I-3, RS-I-4, and RS-I-5 refer to re-examinations of the original
cohort members. RS-II-1 refers to the extension of the cohort with
persons in the study district that became 55 years since the start of the
study or those of 55 years or over that migrated into the study district.
RS-II-2 and RS-II-3 refer to re-examinations of the extension cohort.
RS-III-1 refers to the baseline examination of all persons aged
45 years and over living in the study district that had not been
examined already (i.e., mainly comprising those aged 45–60 years).
RS-III-2 refers to the first re-examination of this third cohort which
will be completed by the end of 2013. Examination RS-I-4 and RS-II-
2 were conducted as one project and feature an identical research
program. Similarly, examinations RS-I-5, RS-II-3, and RSIII-2 share
the same program items
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Heart failure and atrial fibrillation
The Rotterdam Study enabled accurate assessment of the
incidence and lifetime risk of heart failure and atrial
fibrillation in an elderly population [23–25]. It was shown
that inflammation and resting heart rate is associated with
risk of heart failure [26, 27]. In addition we identified
several new risk factors of atrial fibrillation. We found that
markers of generalized atherosclerosis in persons without a
history of myocardial infarction or angina were associated
with a higher risk of atrial fibrillation [28]. Furthermore,
high-normal thyroid function [29] and higher levels of
dehydroepiandrosterone sulfate, a precursor in the biosyn-
thetic pathway of androgenic and estrogenic sex hormones
were associated with incidence of atrial fibrillation [30]. In
collaboration with several community-based prospective
studies we were able to develop a prediction model for
atrial fibrillation, only using variables that are routinely
collected in primary care settings [31]. In a large collabo-
rative study as part of the CHARGE consortium, we
investigated the genetic variation responsible for 6 traits
related to cardiac structure and function. We found two
replicated loci for left ventricular dimension and 5 repli-
cated loci for aortic root size [32]. Another topic of interest
was the search for genetic determinants of several rhythm
and conduction disturbances on the ECG, notably RR-
interval, QRS duration, and QT(c)-interval, PR-interval, as
well as atrial fibrillation and sudden cardiac death. For
example, we identified several new loci for PR interval
[33], heart rate [34], and atrial fibrillation [35, 36] in meta-
analyses from the CHARGE consortium.
Cardiovascular risk factors and prediction
Endocrine, inflammatory and hemostatic factors and risk of
coronary heart disease were addressed in several studies.
Subclinical hypothyroidism was an independent risk factor
of atherosclerosis and myocardial infarction in older
women [37]. In a recent study, we compared the change in
the accuracy of risk predictions when newer risk markers,
representative of various pathophysiologic pathways, were
added to the established clinical risk predictors. Among the
biomarkers, improvements in coronary heart disease risk
prediction were most significant with the addition of
amino-terminal pro-B-type natriuretic peptide (NT-proB-
NP)[38, 39]. Furthermore, plasma C-Reactive protein
(CRP) and lipoprotein-associated phospholipase A2 (Lp-
PLA2) activity were independent predictors of coronary
heart disease [40, 41]. Earlier findings included the asso-
ciation of tissue plasminogen activator (TPA) with incident
coronary heart disease [42]. Recently, we developed and
validated a coronary heart disease prediction model
tailored for the aging population based on competing risk
methodology [43].
Non-invasive measures of atherosclerosis
Multiple studies focused on the predictive value of non-
invasive measures of atherosclerosis for risk of coronary
heart disease. Strong associations with risk of coronary
heart disease were found for carotid intima-media thick-
ness [44], pulse wave velocity [45], and coronary calcifi-
cation as assessed by electron-beam CT [46]. The relatively
crude measures directly assessing plaques in the carotid
artery and abdominal aorta predict coronary heart disease
equally well as the more precisely measured carotid intima-
media thickness [47]. In persons at intermediate risk of
cardiovascular disease, coronary artery calcium provided
the best increment in coronary heart disease risk prediction
and stratification (to reclassify persons into more appro-
priate coronary risk categories)[39, 48]. The burden of
coronary calcification also provides incremental predictive
information for heart failure, but not for cerebrovascular
disease [49, 50].
Genetic studies
Genetic studies included candidate gene studies [51] and
more recently genome-wide association studies of clinical
disease and risk factor phenotypes. So far we have con-
tributed to more than 100 Genome-wide association
(GWA) studies in the field of cardiovascular disease. These
GWA studies are primarily conducted in the framework of
the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [52, 53] however in
many instances we include further studies. We identified 3
genetic loci associated with uric acid concentration and
gout [54].
We also identified a significant association between the
UMOD gene which encodes Tamm-Horsfall protein and
chronic kidney disease [55]. We found four genes for
systolic blood pressure, six for diastolic blood pressure and
one for hypertension [56–58]. We found multiple loci that
influenced erythrocyte phenotypes in the CHARGE Con-
sortium [59]. In a meta-analysis in more than 80,000
individuals from 25 studies, we identified 18 loci for CRP
levels. The study highlighted immune response and meta-
bolic regulatory pathways involved in the regulation of
chronic inflammation [60]. Novel associations of multiple
genetic loci with plasma levels of factor VII, factor VIII,
and von Willebrand factor were also detected [61]. We
have also identified genetic loci associated with the mea-
sures of subclinical atherosclerosis burden. Our genome-
wide association studies on the 3 measures of subclinical
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atherosclerosis identified several new genetic loci [62–64].
We have contributed to GWA studies on coronary artery
disease [65, 66].
Nutrition and lifestyle
We found that subjects who had fish intake of more than
19 g/day had a significantly lower prevalence of mild/
moderate coronary calcification [67]. Also, we found that
an increase of 50 g in processed meat was associated with
increased CRP levels [68]. In addition to this, the intake of
processed meat was associated with a higher risk of type 2
diabetes which was independent of CRP levels [68].
Likewise, we studied whether dietary proteins, amino acids
and acid load were associated with the risk of hypertension.
It appeared that these factors were not a major determinant
of the risk of hypertension in the Rotterdam Study [69–
71].Besides main effects of nutrition, we studied gene-
nutrient interactions. We found that dietary vitamin E
intake may modulate the relation of SIRT1 genetic variants
with body mass index [72]. Also, we studied the modifi-
cation of magnesium, whole grain and a healthy diet score
on fasting glucose and insulin by SNPs related to fasting
glucose and insulin as part of the CHARGE consortium
[73–75].
Methods update
Clinical follow-up
Information on clinical cardiovascular outcomes is col-
lected through an automated follow-up system. The follow-
up system involves linkage of the study base to digital
medical records from general practitioners in the study area
and subsequent collection of letters of medical specialists
and discharge reports in case of hospitalisation. With
respect to the vital status of participants, information is also
obtained regularly from the municipal health authorities in
Rotterdam. After notification, cause and circumstances of
death are established by questionnaire from the treating
physicians. Clinical cardiovascular outcomes are adjudi-
cated according to established definitions based on inter-
national guidelines by study physicians and medical
specialists in the field affiliated with the Rotterdam Study.
Methods of follow-up data collection, adjudication of
events, and definitions of cardiovascular end points have
been described in detail previously in this journal [14].
Systematic follow-up data collection is done for the
occurrence of cardiovascular mortality, coronary heart
disease (including coronary death, myocardial infarction,
and coronary revascularization procedures), heart failure,
atrial fibrillation, and sudden cardiac death [14]. Diabetes
mellitus is defined based on guidelines of the American
Diabetes Association and the World Health Organization.
We defined incident diabetes as fasting plasma glucose
level C7.0 mmol/L, or the use of oral antidiabetic medi-
cation or insulin, or treatment by diet and registered by a
general practitioner as having diabetes.
Cardiovascular risk factors
Besides traditional cardiovascular risk factors, five major
groups of putative risk factors for cardiovascular conditions
are examined. The first group are lifestyle factors, includ-
ing dietary factors, physical activity, smoking, sleep and
vitamin D (as described above). The second are endocrine
factors, including diabetes, sex hormones, thyroid gland
and adrenal gland hormones and natriuretic peptides (e.g.
[29, 30, 37–39]. The third group comprises factors
involved in hemostasis, inflammation and endothelial
function (e.g. [40, 61, 76]). The fourth group covers genetic
factors. In addition to the candidate gene approach, studies
are more recently conducted through the genome-wide
association approach (e.g. [32–36, 54–66, 73–75]). In
genome-wide association studies, data from the Rotterdam
Study are often combined with those from other studies in
the context of the large collaborative CHARGE consortium
[52, 53]. Within the fifth group we are applying both proton
Nuclear Magnetic Resonance (1H NMR) and Mass Spec-
trometry (MS) for metabolic profiling in 2,000 participants
of the Rotterdam Study including nearly 200 incident cases
of coronary heart disease. Furthermore, in this context,
special attention has been given to the contribution of
different risk factors in relation to cardiovascular disease in
women. Data has been collected to evaluate the impact of
specific periods of potential vulnerability across a woman’s
lifespan; menarche, pregnancy, and menopause.
Non-invasive measures of atherosclerosis
At baseline and follow-up examinations, ultrasonographic
assessments of carotid intima-media thickness and carotid
plaques were conducted in all participants [44]. At these
examinations, also measurements of the ankle-brachial
index and aortic calcification (on X-rays of the lumbar
spine) were obtained [14]. Carotid–femoral pulse wave
velocity, a measure of aortic stiffness, was measured in all
*participants of RS-I-3, RS-II-1, and RS-III-1 with an
automatic device [45]. Measurements of coronary calcifi-
cation by electron-beam CT and more recently by MDCT
were conducted from 1997 onwards in RS-I and RS-II [46,
48]. From 2003 to 2006, MDCT was used to also quantify
calcification in the aortic arch and carotid arteries in RS-I
and RS-II. Measurement of carotid plaque components
using MRI was done from 2007 to 2012 in all participants
The Rotterdam Study 893
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from RS-I, RS-II and RS-III with carotid wall thickening
on conventional carotid ultrasound. Repeated MRI mea-
sures over time were obtained in RS-I and RS-II.
Electrocardiographic, echocardiographic and other
ultrasound measurements
At every exam, a 12-lead 10-second resting ECG is made
and processed by the Modular ECG Analysis System
(MEANS) to obtain a series of ECG measurements [77].
Abdominal aortic diameters were measured by ultrasound
at RS-I-1, and from 2002 (RS-I-4) onwards in all three
Rotterdam Study cohorts. Also from 2002 onwards (RS-I-
4), repeated echocardiographic measurements are con-
ducted of structural and functional left heart parameters
[78]. From 2009 (RS-I-5) onwards, measurements of
structure and function of the right heart are also collected,
including estimates of pulmonary artery pressure. In the
same round a 3-minute resting ECG was measured in all
participants.
Nutrition and lifestyle
Nutritional data has been collected in RS-I-1, RS-I-5, RS-
II-1, RS-II-3 and RS-III-1 by using semi quantitative food
frequency questionnaires (FFQ). In RS-I-1 and RS- II-1,
participants completed a checklist about foods and drinks
they had consumed at least twice a month during the pre-
ceding year and a standardized interview using a validated
170-item semi-quantitative FFQ [79]. In RS-I-5, RS-II-3
and RS-III-I, a more comprehensive FFQ was used during
the visits as described in detail previously [80–83].
Development and processing of nutrition data is being
performed in close collaboration with the Department of
Human Nutrition, Wageningen University, the Nether-
lands. In RS-I-III, RS-I-5, RS-II-I-3 and RS-III-I, physical
activity data was assessed by means of an adapted version
of the Zutphen Physical Activity Questionnaire and the
LASA Physical Activity Questionnaire [84–86]. The
questionnaire contained questions on walking, cycling,
gardening, diverse sports, hobbies and on housekeeping.
According to time spent in light, moderate and vigorous
activity, metabolic equivalents of task were calculated.
For additional EJE references concerning cardiovascular
disease see [12, 87–136].
Dermatological diseases
Objectives
Dermatoepidemiologic research in the Rotterdam Study
focuses on the frequency of the most common skin
conditions as well as on genetic and environmental factors
associated with these skin diseases. The emphasis is on
cutaneous malignancies such as basal and squamous cell
carcinomas (BCC and SCC, respectively) and their pre-
cursor lesions (actinic keratosis), inflammatory dermatoses
such as eczema and psoriasis, and varicose veins. Also, we
examine the frequency and determinants including genetics
and environmental exposures of skin aging (pigmentation,
wrinkling and photodamage).
Methods
In 2010, dermatology studies were introduced in the Rot-
terdam Study. To the home interview several items have
been added questioning ultraviolet light exposure, history
of (personal and familial) psoriasis, history of skin cancer,
the diagnostic criteria of British association of dermatology
for atopic eczema, adjusted diagnostic criteria for psoriatic
arthritis.
A full body skin examination by physicians trained in
dermatology with a focus on the most common skin dis-
eases is the core contribution of dermatology. The clinical
presence and extent of specific skin diseases (i.e., actinic
keratosis, malignancies, psoriasis, xerosis, hand and flex-
ural eczema, alopecia, and signs of chronic venous insuf-
ficiency based on the ‘C’ of the CEAP classification) at
time of examination is assessed in a standardized fashion.
Other dermatological diseases will just be noted.
The extent of skin aging as a global score and broken
down in different aspects such as wrinkling, pigmentary
spots, and teleangiecatsia are scored using a validated
photonumeric scales and computer algoritms. The Nor-
wood-Hamilton classification and the Ludwig classification
is used for male and female pattern hair loss, respectively.
Fully standardized 3-dimensional photographs (Premier
3dMDface3-plus UHD, Atlanta, USA) of the face are taken
to further assess skin characteristics. The colour of the
facial skin and at the inner side of the upper arm are
measured using a spectrophotometer (Konica Minolta
Sensing, spectrophotometer CM-700d, Singapore).
As for other cancers, pathology data of the cutaneous
malignancies is obtained from linkage to the national
cancer registry and the Dutch pathology database (PAL-
GA). In a further attempt to identify cohort members with
psoriasis, medical files and dispenses at pharmacies have
been investigated resulting in over 350 psoriasis cases.
Major findings
In the first follow-up study including the skin examinations
of more than 2,000 cohort members, showed that actinic
keratosis is very common in this elderly population (AK
prevalence was 49 % for men and 28 % for women) [137].
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After adjusting for other factors, baldness in men was
associated with a strongly increased risk of actinic
keratosis.
The first prevalence study of single and multiple BCC was
done in the Rotterdam Study and showed that a total of 524
patients (4.8 % of included population) had developed this
type of keratinocytic cancer and that 31.1 % had developed
more than one tumor during observation [138]. A multi-failure
survival model suggested that people with red hair and higher
levels of education, and those who had their first BCC at
younger age were significantly more likely to develop multi-
ple malignancies. A recent update yielded more than 1,350
participants with a history of BCC and approximately 450
with a SCC. In collaboration with researchers from the Nurses
Health Study, the association between common genetic vari-
ants and these skin cancers is currently being examined.
In a candidate gene study in almost 6,000 people, we
confirmed known and identified new variants associated
with digital skin colour extraction. Of the two new skin
color genes, the genetic variants in UGT1A were signifi-
cantly associated with hue and variants in BNC2 were
significantly associated with saturation [139].
The psoriasis patients within the Rotterdam Study had
predominantly mild disease. The distribution of subclinical
artherosclerosis measures as well as the cardiovascular
events were comparable between the 262 psoriasis patients
and the reference population [140]. However, psoriasis
patients were significantly more likely to have signs of
nonalcoholic fatty liver disease based on ultrasonography
than their controls after adjusting for potential confounders
(adjusted OR 1.70, 95 % CI 1.13–2.58).
Endocrine diseases
Objectives
The main objective of the programme of endocrine epi-
demiology research is to study frequency and etiology of
major disorders of the endocrine glands (pituitary, repro-
ductive, thyroid, parathyroid, adrenal, and neuro-endocrine
pancreas) and the musculoskeletal system. These include
diabetes mellitus, osteoporosis, osteoarthritis, reproductive
traits (fertility, age-at-menopause), and hypo- and hyper-
thyroidism. The evaluation of risk factors for the above
mentioned conditions includes serum measurements (such
as classical hormones and other endocrine molecules) and
genetic determinants of endocrine diseases and traits.
Major findings
In the process of obtaining digitized Xrays for all partici-
pants at all time-points of follow-up, we have evaluated the
3 major methods to score vertebral fractures: quantitative
morphometry, semi-quantitative morphometry, and the
qualitative ABQ method [141]. Prevalence of vertebral
fractures differed substantially by the different methods, so
standardization is crucial for patient care and for large
scale epidemiological studies. Using the digitized Xray
scores, we have for the first time determined population-
based prevalence of Scheuermann’s disease in the Dutch
population to be 4 % [142].
In the relationship of type 2 diabetes with bone health
we observed that diabetic subjects with inadequately con-
trolled glucose control had 1–5 % increased bone mineral
density (BMD) and *50 % increased fracture risk, com-
pared to diabetics with adequately controlled glucose and
to non-diabetics [143].
By studying bone health across different types of hip
osteoarthritis (OA), we observed that subjects with atrophic
OA (i.e., with joint space narrowing but without osteo-
phytes) have *50 % increased fracture risk as compared
to controls without OA [144]. In addition, we found that
hip geometry measures had modest ability to predict hip
OA, in addition to clinical risk factors [145].
The research line endocrine diseases is also actively
involved in collaborating with economists to study the
biology of economic behaviour, in particular entrepre-
neurial behaviour (and related traits such as educational
attainment). In one of the first collaborative analyses we
found no evidence for a relationship of testosteron levels
with entrepreneurial behaviour [146].
Much of the work of this research is made possible by
large-scale collaboration in consortia, some of which focus
on one particular disease or trait (e.g., GEFOS), while
others are more broad spectrum strategic collaborations
(e.g., CHARGE, ENGAGE). We are part of several such
large consortia studying genetic and epidemiological risk
factors for osteoporosis (GEFOS, GENOMOS, CHAN-
CES, CHARGE), osteoarthritis (TREAT-OA, ArcoGen),
diabetes (MAGIC), thyroid disease (CHARGE), and
reproductive traits (CHARGE, REPROGEN, PCOSGEN).
Major GWAS findings
With [82,000 samples collected within the GEFOS con-
sortium a landmark publication was achieved with the
identification of 56 loci influencing bone mineral density in
total explaining *5 % of genetic variation in BMD, and of
which 14 loci also were associated with fracture risk [147].
In a meta-analysis of 15,000 hip OA cases and 54,000
controls assembled in the arcOGen consortium, 5 novel
loci influencing risk of hip OA were identified [148]. In an
analysis of a so-called endo-phenotype of OA, i.e., joint
space width narrowing (JSN) a GWAS among 10,000
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subjects we identified a novel locus, called DOT1L, to
influence cartilage thickness, as well as the risk for hip OA
[149]. Interestingly, this gene product is a known drug
target for treating leukemia with several drugs under
development. Experiments are therefore now ongoing to
evaluate the effect of these drugs on features of OA in
animal and cell model systems. Finally, in the analysis of
another endophenotype of OA, pain, our group led a large
scale meta-analysis to chronic wide spread pain in 2700
cases and 14,000 controls and identified for the first time a
genetic locus involved in pain, i.e., CCT5 [150].
In the largest meta-analysis of GWAS of age-at-meno-
pause among 62,000 women and which our group led, we
identified 13 loci associated with differences in age-at-
menopause and explaining *5 % of the genetic variation
[151]. Interestingly, the majority of the loci most likely
involves genes in the DNA repair pathway which points to
the importance of this system in maintaining an error-free
stemcell lineage to which the oocyte belongs.
In a meta-analysis of GWAS data on TSH levels and
free T4 levels derived from up to 26,000 subjects, 26 loci
were identified explaining 2–5 % of the genetic variation
of TSH and fT4 respectively [152]. There was only limited
overlap between the loci for TSH and fT4, and evidence
was obtained for 5 loci to have sex-specific effects.
An interesting GWAS involved the analysis of Helico-
bacter pylori serologic status among members of the Rot-
terdam Study and the SHIP cohort [153]. Two novel loci
were identified, TLR1 and FCGR2A, which can help explain
inter-individual differences in risk for H pylori infection.
For many endocrine biomarkers GWAS have been
performed to identify the genetic loci influencing their
serum levels (e.g., homocysteine, testosteron, SHBG, thy-
roid hormone levels, etc.) and these are also involved in
several mendelian randomization analyses in relation to
major disease endpoints for which these biomarkers have
been suggested to be predictive.
Methods update
For all participants DXA-based bone mineral density
(BMD) measurements of the lumbar spine, dual hip and
total body BMD, as well as determination of body com-
position parameters are assessed with a ProdigyTM total
body fan-beam densitometer (GE Lunar Corp, Madison,
WI, USA). Hip structural analysis (HSA) of DXA scans
including hip strength indexes (using software by GE
Lunar) is determined for all scans. Since 2009 we perform
iDXA measurements (GE Lunar) which measures L1–L4
BMD, bilateral total hip and femoral neck BMD and total
body BMD. From the total body scan, we measure lean
mass and fat mass body composition, including total body,
trunk, arm, legs, and android and gynoid regions of
interest. X-ray examinations of vertebral bodies, hips,
knees and hand/wrist are since 2009 obtained by a digi-
talized Fuji FCR system (FUJIFILM Medical Systems) for
all participants. Analogue Xray photographs from previous
time –points at all follow up measurements (*75,000
Xrays) have now all been digitized. All the Xrays have now
been completely assessed for the presence of fractures and/
or degenerative changes of the joints (e.g., Scheuermann’s
Disease). Vertebral fractures and deformities are assessed
using the classical quantitative McCloskey-Kanis method,
the semi-quantitative Genant method, and a qualitative
algorithm-based technique termed the ABQ method. Inci-
dent clinical fractures (of all bone sites) are obtained from
computerized records of the general practitioners and
hospital registries which are regularly checked by research
physicians who review and code the fracture information.
Muscle strength is assessed in all participants with a
hand grip dynamometer. Muscle mass estimates are
derived from whole body iDXA measurements.
The incidence and progression of OA is assessed using
Kellgren scores obtained from X-rays of hips, knees,
hands, and spine. The complete set of X-rays (all partici-
pants, all follow-up time points) has now been evaluated
for the Kellgren score at these 4 joints. Novel diagnostic
assessments for OA are available using Magnetic Reso-
nance Imaging (MRI) of the knees in a large subset of the
population (n = * 1,000 RS-III). In addition, pain mea-
surements were added in 2011 in this research line
including a quantitative assessment of heat sensitivity on
the arm using a standardized device, and indications of
(wide-spread) pain in any part of the body using a puppet.
Several specific biomarker assessments in blood/serum/
plasma and urine are done for the diagnosis and evaluation of
risk factors of endocrine and metabolic diseases (e.g., glu-
cose, TSH, freeT4, steroid hormones, calcium, CTXII, etc.).
Fasting blood samples are collected along with challenged
samples as part of a glucose tolerance test. Sputum is col-
lected before and after a dexamethasone-suppression test.
Finally, validated questionnaires evaluating nutrient intake
(e.g., calcium and vitamins) and activities of daily living,
allow to evaluate the role of environmental factors in endo-
crine conditions and locomotor diseases of the elderly.
For additional EJE references concerning endocrine
diseases see [154–173].
Liver diseases
Objectives
Fibrogenesis of the liver is most probably not only the
result of well known liver diseases, such as viral hepatitis,
alcoholic liver disease or non-alcoholic fatty liver disease
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(NAFLD), but rather a complex interaction between a
genetic predisposition and these liver disorders. Liver
research in the Rotterdam Study will concern the associa-
tion between these known causes of liver disease and the
occurrence, magnitude, and progression of fibrosis in
combination with genetic and environmental factors.
Additional research focus will be on NAFLD. NAFLD is
considered the hepatic manifestation of the metabolic
syndrome and has become the most common chronic liver
disease in Western countries in parallel with epidemics of
obesity and type II diabetes mellitus. We aim to study the
occurrence and risk factors of NAFLD in a general popu-
lation and generate insight into the association with car-
diovascular morbidity and mortality.
Methods
Abdominal ultrasound
From February 2009 trained technicians perform abdomi-
nal ultrasonography in Rotterdam Study participants.
Liver, biliary tract, gall bladder, spleen, pancreas, and
kidneys in combination with doppler examination of
hepatic veins, hepatic artery and portal vein will be eval-
uated. All images are stored digitally and will be reevalu-
ated by an ultrasound trained physician.
Assessment of steatosis
The diagnosis and grading of liver steatosis will be based
on ultrasonographic liver brightness, hepatorenal echo
contrast, deep attenuation and vessel blurring [174].
Non alcoholic fatty liver is diagnosed by presence of
steatosis on ultrasound and exclusion of excessive alcohol
consumption, presence of viral hepatitis, use of fatty liver
inducing pharmacological agents, recent bariatric surgery
and a history of inflammatory bowel disease.
Assessment of fibrosis
Ultrasonographic evaluation of the liver parenchyma and
liver surface will be performed in order to assess severe
fibrosis and/or cirrhosis. Additionally, sonographic signs of
portal hypertension will be studied (splenomegaly, venous
collaterals, portal vein diameter and flow, hepatic venous
flow, and the presence of ascites).
To assess and quantify the grade of fibrosis trained
technicians will perform elastography in all participants.
This test measures non-invasively and quantitatively the
liver stiffness using a probe which includes an ultrasonic
transducer transmitting a vibration wave through the liver.
The velocity of the ultrasonic wave correlates directly with
tissue stiffness [175, 176].
Determinants of interest
The association between factors known to influence liver
function and the occurrence of steatosis and fibrosis will be
studied. Additionally the association of these conditions
with age, gender, nutritional intake, concurrent alcohol
intake, risk factors for viral hepatitis, BMI, waist-to-hip
ratio, serum glucose, insulin, and diabetes mellitus, serum
cholesterol and triglycerides will be studied. All clinical
information will be obtained by interview (updated with
liver specific questions) and clinical examination. For
recent EJE references see [91, 177–180].
Neurological diseases
Objectives
Neuroepidemiologic research in the Rotterdam Study
focuses on the frequency, etiology and early recognition of
the most frequent neurologic diseases in the elderly. We
study neurodegenerative diseases (dementia, including
Alzheimer disease and Parkinson disease), cerebrovascular
disease (both ischemic stroke and intracerebral hemor-
rhage), and recently migraine and polyneuropathy. In all of
these disorders clinical symptoms typically become mani-
fest late in the disease course, the occurrence of clinical
disease does not reflect the underlying spectrum of disease-
related pathology, and most of the clinical syndromes are
etiologically heterogeneous. Therefore, an additional
research focus is on the causes and consequences of pre-
symptomatic brain pathology that can be assessed with
non-invasive modalities, which include MR-imaging,
cognitive testing, gait assessment, and recently electro-
myography (EMG).
Major findings
Neurodegenerative and cerebrovascular diseases are highly
frequent in the elderly. The prevalence increases from age
55–65 years to age 90 years and above from less than 1 %
to over 40 % for dementia [181], from less than 0.5 % to
more than 4 % for Parkinson disease [182], and from
approximately 1 % to nearly 10 % for stroke. The inci-
dence figures follow this pattern of a strong increase with
age over the entire age range, with the age-specific inci-
dence of dementia being identical for men and women at
least until the age of 85 [183] but with men having a higher
age-specific incidence of both stroke and Parkinson disease
than women throughout the age range [184, 185].
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However, more recent numbers from 2000 onwards suggest
that the relative incidence of dementia and stroke may be
lower than in the 1990s [186–188]. Still, in absolute
numbers these disease will dramatically increase in prev-
alence over the coming decades.
Vascular pathology and vascular risk factors are asso-
ciated with worse cognitive performance [189], which also
translates in people with vascular pathology or risk factors
for vascular disease having an increased risk of dementia,
including Alzheimer disease [190]. Moreover, several life
style factors are associated with the risk of dementia and
Alzheimer disease [191, 192], suggesting that onset of
dementia may at least partly be delayed or prevented.
However, many of these lifestyle factors have only a short-
term effect, suggesting reverse causality to some extent
[193]. Commonly used drugs may also have a role in
development of dementia [194]. Similar risk factor profiles
also underlie cognitive decline prior to the clinical diag-
nosis of dementia [195, 196].
The classical risk factors for stroke also associate with
the risk of stroke in the Rotterdam Study [197, 198]. In
contrast, some emerging putative risk factors are not
associated with stroke [199], whilst others, such as
inflammatory markers, may be etiologically relevant but
thus far add little to the identification of people at risk
[200]. Possibly underlying this is that a large amount of
stroke goes clinically undetected [201]. Nearly 20 % of
elderly people have at least one silent brain infarct, and
thereby a nearly fourfold increased risk of clinical stroke, a
more than doubled risk of dementia including Alzheimer
disease, and an increased risk of depression [202].
With the advent of genome-wide association studies, the
Rotterdam Study has contributed to large-scale collabora-
tions and contributed to the identification of novel genes
underlying the risk of Alzheimer disease and stroke [203–
205]. In turn, we have also shown that although currently
known genetic variants for dementia associate with cog-
nition in non-demented elderly, these do not improve
prediction [206].
Neuroimaging reveals that brain pathology is wide-
spread [207] and can go clinically undetected for a long
time. In addition to the silent infarcts, many apparently
healthy elderly have ischemic changes in their cerebral
white matter, i.e. white matter lesions, that are associated
with an increased risk of dementia, stroke and depression.
Also brain atrophy, especially of the hippocampus, is
already present years before onset of even the earliest sign
of cognitive impairment or subjective complaints. This
emphasizes the need to shift the attention in etiologic
research of neurodegenerative and cerebrovascular disease
to the causes of pre-symptomatic and underlying brain
changes. Technological advances in image acquisition,
optimized imaging sequences and automated post-
processing of multispectral MR data are major drivers of
the rapid developments in this field. With our current
imaging protocol we can now not only investigate estab-
lished markers of brain pathology, such as infarcts, white
matter lesions, and atrophy, but also extend towards novel
markers, such as cerebral microbleeds and diffusion tensor
imaging [208]. We have shown that risk factors profiles for
subclinical disease overlap with those for clinical disease
[209–213]. Also, subclinical white matter lesions and silent
infarcts improve the clinical prediction of incident stroke
[214]. The clinical relevance of subclinical pathology is
demonstrated by strong associations of these markers with
morbidity and mortality [215–218].
Finally, we have extensively studied the genetic basis of
subclinical brain disease, both in genome-wide settings and
in candidate-gene studies [219–225] (see further section on
population imaging).
Most research on the preclinical phase of neurodegenera-
tive diseases, particularly dementia, focuses on either cogni-
tive performance or brain pathology on neuroimaging. Given
that brain pathology is usually diffuse, it is conceivable that
brain functions other than cognition will also be affected. In
this light, we have shown that gait deteriorates significantly
with age. Also, gait and cognition are linked following a
specific pattern of certain cognitive domains only associated
with specific aspects of gait, but not others [226] .
Methods update
Assessment of dementia and Alzheimer disease
In the baseline and follow-up examinations participants
undergo an initial screen for dementia with the Mini
Mental State Examination (MMSE) and the Geriatric
Mental Schedule (GMS), followed by an examination and
informant interview with the Cambridge Examination for
Mental Disorders of the Elderly (CAMDEX) in screenpo-
sitives (MMSE \ 26 or GMS [ 0), and subsequent neu-
rological, neuropsychological and neuroimaging
examinations [181, 183]. Of subjects who cannot be
reexamined in person, information is obtained from the
GPs and the regional institute for outpatient mental health
care. A consensus panel makes the final diagnoses in
accordance with standard criteria (DSM-III-R criteria;
NINCDS-ADRDA; NINDS-AIREN).
Assessment of Parkinsonism and Parkinson disease
Participants are screened in the baseline and follow-up
examinations for cardinal signs of parkinsonism (resting
tremor, rigidity, bradykinesia, or impaired postural
reflexes). Persons with at least one sign present are
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examined with the Unified Parkinson’s Disease Rating
Scale and a further neurologic exam. PD is diagnosed if
two or more cardinal signs are present in a subject not
taking antiparkinsonian drugs, or if at least one sign has
improved through medication, and when all causes of
secondary parkinsonism (dementia, use of neuroleptics,
cerebrovascular disease, multiple system atrophy, or pro-
gressive supranuclear palsy) can be excluded [182, 185].
Assessment of stroke and stroke subtypes
History of stroke at baseline was assessed through inter-
view and verified in medical records. Putative incident
strokes get identified through the linkage of the study
database with files from general practitioners, the munici-
pality, and nursing home physicians’ files, after which
additional information (including brain imaging) is col-
lected from hospital records. A panel discusses all potential
strokes and subclassifies strokes into ischemic, hemor-
rhagic or unspecified [184, 200]. We also systematically
collect transient ischemic and neurological attacks [227].
Assessment of cognitive function
Global cognitive function is measured through the Mini
Mental State Examination (MMSE) in all surveys. From
the third survey (RS-I-3) onwards we added a 30 min test
battery that was designed to assess executive function and
memory function, and which includes a Stroop test, a
Letter Digit Substitution Task, a Word Fluency Test, and a
15 words Word List Learning test. This test battery was
expanded from the fourth survey onwards (RS-I-4) to
include motor function assessment using the Purdue Peg-
board Test. Moreover, from 2009 onwards we expanded
further by including the Design Orientation Test (DOT)
and a modified version of the International Cooperative
Ataxia Rating Scale (ICARS), which assess visuo-spatial
orientation and ataxia respectively [228, 229].
Assessment of gait patterns
Halfway through RS-III-1, we successfully implemented the
assessment of gait in all participants using the GAITRite
walkway (http://www.gaitrite.com/). Gait is assessed using a
5.79 meter long walkway (GAITRite Platinum; CIR sys-
tems, Sparta, NJ, USA: 4.88 meter active area; 120 Hertz
sampling rate) with pressure sensors. Participants perform a
standardized gait protocol consisting of three different
walking conditions: normal walk, turning and tandem walk.
In the normal walk, participants walk over the walkway at
their own pace. This walk is repeated four times in both
directions (yielding a total of 8 recordings). In turning, par-
ticipants walk over the walkway at their own pace, turn
halfway and return to the starting position (1 recording). In
the tandem walk, participants walk tandem (heel-to-toe) over
a line visible on the walkway (1 recording). A total of 30
spatiotemporal gait variables are calculated by the walkway
software and downloaded offline for further analysis. Sub-
sequently, principal components analysis on these thirty gait
variables is performed to derive summarizing factors,
referred to as gait domains. The following gait domains are
used: Rhythm, Pace, Phases, Base of Support, Variability,
Tandem, and Turn. Gait domains can be compared to cog-
nitive domains, in which each domain reflects a different
aspect of the overall concept [226].
Assessment of polyneuropathy
Starting in January 2013, we have successfully imple-
mented a protocol to assess polyneuropathy. This includes
a full work-up including questionnaire, neurological exam,
and EMG in all participants. In coming years, we will
publish on the prevalence, risk factors, and clinical corre-
lates of polyneuropathy in the general population. The
continuous measures of conductivity obtained through
EMG can also serve as excellent endophenotype for
genetic and biomarker studies.
Rotterdam Scan Study: brain imaging within the Rotterdam
Study
In 1991, a random sample of 111 participants underwent
axial T2-weighted magnetic resonance (MR) imaging to
assess presence and severity of white matter lesions [207].
In 1995, a random sample of 563 non-demented partici-
pants underwent brain MR imaging in the context of the
Rotterdam Scan Study. From August 2005 onwards (RS-II-
2 and further), a dedicated 1.5 Tesla scanner is operational
in the research center of the Rotterdam Study, and brain
imaging is performed in all study participants without
contra-indications [208].
Currently, the follow-up of this latter sample extends to
up to 7 years. Therefore, in the coming years we will be
able to investigate how cerebral microbleeds and DTI-
markers relate to incident neurological diseases (see further
section on population imaging).
For additional EJE references see [230–241].
Ophthalmic diseases
Objectives
The main objectives of the ophthalmic epidemiology
studies are to investigate frequency, genetic and
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environmental risk factors, their interaction, (endo)pheno-
typic characteristics, and potential biomarkers or disease
intermediates of frequently occurring complex eye disor-
ders. We particularly focus on age-related macular
degeneration, open angle glaucoma, and myopia; other
areas of interest are retinal vessel diameters, and diabetic or
vascular retinopathy.
Major findings
Age-related macular degeneration (AMD)
Although many major genes for AMD have already been
identified these last years, missing heritability was still
abundantly present. To identify more genes, we combined
our efforts with international study groups which had a
total study population consisting of 17,100 advanced AMD
cases and [ 60,000 control subjects [242]. Within this
AMDGene consortium, 7 new genetic regions (COL8A1/
FILIP1L; IER3/DDR1; SLC16A8; TGFBR1; RAD51B;
ADAMTS9/MIR548A2; B3GALTL) for AMD were found.
Taken together with the already known genes, a total of 19
AMD genes were identified in this consortium. Highest
genetic associations were found for the ARMS2 and CFH
genes. The pathogenetic pathways that can be deduced
from these genes are the complement pathway, athero-
sclerosis signaling and lipid pathway, angiogenesis, and
extra-cellular matrix remodeling. Further steps to diminish
missing heritability are identification of genetic variants by
NGSexome sequencing. This is the focus of attention of the
newly formed AMDExome Chip consortium.
To perform more extensive analyses involving genetic
as well as other risk factors, we also searched for con-
nection with international studies. The 3 Continent AMD
Consortium was established, a consortium of four popula-
tion-based studies: Beaver Dam Eye Study (BDES) [243]
and Los Angeles Latino Eye Study (LALES) [244] from
the United States; Blue Mountain Eye Study (BMES) from
Australia [245], and our own Rotterdam Study (RS) from
the Netherlands. The total study population of this con-
sortium is 25,000 subjects aged 45 ? years, and many of
these subjects have been followed for [15 years. A first
effort of the consortium was harmonizing the outcome
variable AMD, and a new severity scale was launched.
Secondly, a detailed analysis of gene-diet interaction was
performed, showing that the major AMD genes interact
with the anti-oxidants lutein/zeaxanthin. Thirdly, we
developed a prediction model for late AMD based on well-
known genetic and environmental risk factors, age, sex,
and early AMD phenotype. Incorporation of all these fac-
tors provided a predictive value of 0.88 (area under the
curve; AUC) to predict late AMD in the discovery cohort
the Rotterdam Study, and a predictive value of 0.85 (AUC)
in the BDES and BMES at validation. The prediction
model enabled distinction between those with virtually no
risk of late AMD and those with up to 65 % cumulative
risk. We think these findings will be useful for clinicians as
well as researchers. They may facilitate recognition of high
risk individuals who need life style advice to diminish their
risk, as well as identification of a suitable study population
for intervention trials.
Research aims for 2013 are evaluation of gene and gene-
environment effects on (sub)clinical manifestations of
disease as visible on various imaging devices (OCT; fundus
autofluorescence; infrared); or as systemic biomarkers; and
interaction with medication.
Open angle glaucoma (POAG)
After a first attempt was made to identify genes for optic
disc parameters in 2011, we now investigated the genetic
factors for intraocular pressure (IOP) in the Rotterdam
Study. IOP is a highly heritable risk factor for primary
open-angle glaucoma and is the only target for current
glaucoma therapy. We performed a GWAS for IOP in
11,972 participants from the 3 Rotterdam Studies and ERF
[246]. We then replicated our findings in 7,482 participants
from 4 additional cohorts from the UK, Australia, Canada,
and the Wellcome Trust Case–Control Consortium 2/Blue
Mountains Eye Study. IOP was significantly associated
with GAS7 and TMCO1, and risk variants also appeared to
associate with glaucoma.
The genes are highly expressed in significant eye
structures involved in glaucoma pathogenesis, and we think
we have identified two clinically relevant genes involved in
IOP regulation. Further action in this realm has been the
formation of an international consortium for meta-analyses
of GWAS data. Collaboration was found with 16 studies
from 7 countries including 45,000 study participants,
forming the International Glaucoma Genetics Consortium
(IGGC). Genetic meta-analyses are currently being carried
out.
Relations with environmental factors were studied with
a focus on diet. We found that a low intake of retinol
equivalents and vitamin B1 and a high intake of magne-
sium were associated with an increased risk of OAG [247].
These relations will be further explored.
Imaging of POAG hallmarks on OCT is a relatively new
but competitive field. Quantification of the retinal nerve
fiber and ganglion cell layer measured on multiple images
taken over time would help to establish the early course of
disease, and the use of continuous outcomes to estimate
progression would facilitate statistical analyses. In a col-
laborative study with University of Iowa, we investigated
test–retest variability of measurements on 3-D OCT data.
We found that combined macular RNFL and RGCL
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thickness averaged over larger areas had the best test–retest
variability, and may be the best outcome parameter to use
in future analyses [248].
Future investigations will focus on in-depth elucidation
of the genetic background of POAG, identification of
metabolic factors, further development of techniques to
improve measurements of retinal layers on OCT, risk
modeling, and study of gene-environment interactions.
Myopia
After our successful identification of the first gene for
common refractive errors and myopia in 2010 [249], we
took the initiative to form a consortium with international
GWA studies. CREAM (Consortium Refractive Error And
Myopia) was formed consisting of 45,000 study partici-
pants, and a meta-analysis found 26 significant genomic
loci for refractive error [250]. The new loci include can-
didate genes with functions in neurotransmission (GRIA4),
ion transport (KCNQ5), retinoic acid metabolism (RDH5),
extracellular matrix remodeling (LAMA2 and BMP2) and
eye development (SIX6 and PRSS56). We also confirmed
previously reported associations with GJD2 and RAS-
GRF1. Risk score analysis using associated SNPs showed a
tenfold increased risk of myopia for individuals carrying
the highest genetic load. Our new research is aimed at
further clarification of genetic mechanisms, the study of
interaction with environmental factors such as education,
and search for possible common pathways with glaucoma.
Other actions which will be undertaken is development of a
classification scheme for myopic retinal changes on various
retinal images (photographs; OCT; autofluorescence), and
the study of genotype-phenotype correlations using this
classification.
Methods update
At baseline and follow-up examinations participants
undergo ophthalmic measurements including best-cor-
rected ETDRS visual acuity, refractive error, Goldmann
applanation tonometry, keratometry, slit lamp examination
of the anterior segment and visual field testing. In phar-
macological mydriasis we make 35 color photographs of
the macular area, and 20 simultaneous stereoscopic
imaging of the optic disc and macular area. Since the fourth
follow-up, 35 stereoscopic color photographs of the opti-
cal disc and the macular area were made (RS-I-5). Analog
fundus photography was replaced by stereoscopic digital
imaging of the macular area and optic disc since the third
follow-up examination. Optic nerve head analysis with a
Heidelberg Retina Tomograph, macular pigment density,
and melanin optical density measurements were added
during the third follow-up (RS-I-3). At fourth follow-up
examination, fourier domain optical coherence tomography
of the macular area and optical disc, axial length and width
measurements of cornea, anterior chamber, lens, posterior
chamber and retina measured with Lenstar; and fundus
autofluorescence, infra-red and red-free measurements
were added (RS-I-5).
Classification of AMD, POAG, and retinal vessel
diameters remained unchanged; refractive error was eval-
uated as spherical value ? half cylindrical value, following
clinical standards.
For additional EJE references see [247, 251].
Psychiatric diseases
Objectives
The aim of the psychiatric research in the Rotterdam Study
is to investigate the determinants, correlates and conse-
quences of common psychiatric problems in the elderly.
The focus has been on depressive disorders but anxiety
disorders, sleep disturbances, addiction to smoking, and
complicated grief are also being studied.
Study design update
In the first years of the Rotterdam Study, psychiatric data
collection was very limited. However, in the second visit
most participants were screened for depressive symptoms
and from the third examination onwards (RS-I-3), which
began in 1997, depressive disorders have been ascertained
in all participants. Assessments of anxiety disorders,
sleeping disturbances, and complicated grief were added in
the subsequent examination (RS-I-4) and have been per-
formed in all follow-up visits of RS-I and II, and in the
baseline of RS III. Recent additions to the protocol inclu-
ded a screening for psychotic symptoms and, starting in
January 2012, ambulatory polysomnography.
Major determinants
Psychiatric research in the Rotterdam Study focuses on
biological risk factors. The vascular depression hypothesis
was tested with different measures of atherosclerosis,
arterial stiffness and cerebral blood flow [252]. We also
examined whether blood levels of vitamins and fatty acids,
immune parameters, and markers of folate metabolism
increased the likelihood of depression [253]. Diurnal pat-
terns of cortisol secretion were related to psychiatric and
other disorders such as subclinical atherosclerosis [254].
Only a few candidate gene studies were performed, cur-
rently GWAs data only is analysed in collaborative efforts
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focussing on depressive symptoms, sleep, anxiety and
cortisol [255, 256]. Several studies of brain morphology are
underway [257]. Current data collection includes a dexa-
methasone suppression test to measure hypothalamic–
pituitary–adrenal axis activity in all participants, which is
unique in a population-based study. Also, psychiatric
problems and psychological traits such as happiness, sleep
duration, and depression are increasingly studied as
determinants of health and mortality [258].
Major outcomes
Information on depression is obtained from (a) psychiatric
examinations, (b) self-reported histories of depression,
(c) medical records, and (d) registration of antidepressant
use [259]. The psychiatric examination during follow-up
visits consists of a screening with the Center for Epide-
miologic Studies Depression Scale (CES-D), and in the
screen-positive participants a semi-structured interview
performed by a trained clinician (Schedules for Clinical
Assessment in Neuropsychiatry). To continuously monitor
incidence of depression throughout follow-up, trained
research-assistants scrutinize the medical records of the
general practitioners and copy the information about pos-
sible depressive episodes.
The following anxiety disorders are assessed with a
slightly adapted Munich version of the Composite Inter-
national Diagnostic Interview: generalized anxiety disor-
der, specific and social phobia, agoraphobia without panic
disorder, and panic disorder [260].
Sleep quality and disturbance is measured with the
Pittsburgh Sleep Quality Index. In addition, sleep duration
and fragmentation are assessed with actigraphy, a method
that infers wakefulness and sleep from the presence or
absence of limb movement [261]. In total, nearly 2000 per-
sons participated in this actigraphy study: they wore an
actigraph and kept a sleep diary for, on average, six con-
secutive nights.
Circadian rhythms: Sleep-wake activity patterns over a
week are studied with actigraphy As a marker of circadian
rhythms. In more than 1700 persons we calculated interdaily
stability, i.e. the stability of the rhythm over days and the
intra-daily variability, i.e. the fragmentation of the rhythm.
The Inventory of Complicated Grief is used to identify
traumatic grief [262]. This is a condition distinct from
normal grief and bereavement-related depression, charac-
terized by symptoms like disbelief about the death and
searching for the deceased.
Major findings
Depression: The incidence and recurrence of depression in
the elderly was estimated by continuously monitoring
depression during a follow-up period of, on average,
8 years [259]. In total, 566 depressive syndromes and
1,073 episodes of clinically relevant depressive symptoms
occurred. For depressive syndromes, the incidence rate was
7.0 (95 % CI 6.0–8.3) per 1,000 person-years and the
recurrence rate was 27.5 (95 % CI 23.7–32.1) per 1,000
person-years. The recurrence rate of depressive syndromes
was equal for women and men.
In a series of initial studies we found some evidence for
the vascular depression hypothesis. More severe coronary
and extra-coronary atherosclerosis were associated with a
higher prevalence of depression, as were cerebral haemo-
dynamic changes [252]. However, our data did not support
a specific symptom profile of vascular depression as pre-
viously defined [263]. Most importantly, we found no
longitudinal relation between peripheral atherosclerosis
and incident depression [264]. Recently we prospectively
studied cerebral vascular risk factors such as white matter
lesions, silent infarcts or blood flow in relation to depres-
sion [265]. We found evidence that small vessel disease
predicted the onset of depression. This suggests that ath-
erosclerotic processes in the brain are a specific risk factor
for depression, but provides little support for a vascular
depression phenotype as a distinct entity.
Sleep: We investigated the relationships of sleep dura-
tion with both cardiovascular risk factors and psychiatric
disorders. We found a marked U-shaped association of
actigraphically measured total sleep time with BMI and
obesity [266]. We also investigated and aimed to explain
sex differences in subjective and actigraphic sleep param-
eters [267]. If assessed by diary or interview, elderly
women consistently reported shorter and poorer sleep than
elderly men. In contrast, actigraphic sleep measures
showed shorter and poorer sleep in men. These discrep-
ancies were partly explained by sleep medication use and
alcohol consumption.
Anxiety: We found that prevalent anxiety disorders
fulfilling DSM-IV criteria may be much less co-morbid
with depressive disorders than previously thought if the
disorders are assessed with different diagnostic instru-
ments. On the other hand, a history of depression is very
common in persons with prevalent anxiety disorder [268].
Smoking: Typically, determinants of smoking cessation
are studied by comparing former with current smokers
[269]. We also used a prospective approach of studying
smoking cessation in 1,200 smokers (mean years of
smoking: 40 years, minimum: 10 years). Smoking status
was repeatedly assessed during follow-up every 3- to
4-years. Thus, an individual could contribute any number
of person-years to the analyses. In other words, people
were classified as smokers or quitters. This approach
enabled us to detect a genetic effect on the incidence of
smoking cessation [270].
902 A. Hofman et al.
123
Complicated grief: In our population-based study of
5741 elderly persons, current grief was reported by 1,089
participants, of these 277 (25 % or 4.8 % of total) were
diagnosed with complicated grief, the vast majority of
which had no clinical symptoms of anxiety or depression.
Persons with complicated grief were older, had a lower
level of education, and more often had lost a child [271].
Ongoing work suggests that complicated grief occurs
together with structural brain atrophy more often than
expected by chance.
Genetics of common psychiatric disorders: In the past
year, we have performed a series of genome-wide associ-
ation studies of the above psychiatric and psychological
phenotypes, mostly as part of the CHARGE consortium.
Several analyses have yielded no convincing genome wide
significant results—clearly the initial studies were under-
powered, psychiatric phenotypes do not present very
homogenous entities and are highly polygenetic. Disap-
pointingly, the genome wide analyses of intermediate
phenotype in the field of psychiatry such as cortisol or
executive function have hardly been more successful [256,
272]. To study the genetics of cortisol, we have established
a dedicated consortium of population-based studies:
CORNET.
Finally, ongoing psychiatric research projects examine
whether and how psychological well-being or psychiatric
problems contribute to survival. Most importantly, we are
interested in whether the effects are specific to certain
behaviour or emotions, are independent of confounding by
physical disease, or can be explained by lifestyle, immu-
nological or hormonal regulation [273].
For additional EJE references see [94, 120, 132, 274–
291].
Respiratory diseases
Objectives
The objectives are to investigate the incidence of respira-
tory diseases, to study genetic and environmental risk
factors for these diseases, and the effect of respiratory
diseases on quality of life, hospitalizations and mortality.
The respiratory diseases of interest in the RS encompass
chronic obstructive pulmonary disease (COPD), asthma,
asthma and COPD overlap syndrome, respiratory tract
infections, pneumonia and lung cancer. COPD is defined as
a chronic airway disease characterized by airflow limitation
that is not fully reversible and usually progressive [292].
COPD is a worldwide leading cause of chronic morbidity,
disability and mortality; by 2020, COPD will become the
third most common cause of death worldwide [293]. In
patients with COPD, comorbidities and exacerbations of
COPD contribute to the severity and the prognosis of the
disease. Asthma is characterized by intermittent attacks of
breathlessness, wheezing and cough, often nocturnal or
elicited by exposure to specific allergens (such as house
dust mites, animal danders and pollens) or to non-specific
triggers (such as exercise and cigarette smoke). Although
the onset of asthma is most common during childhood,
asthma can also occur in adulthood [294]. Asthma in the
elderly is underdiagnosed and undertreated, and there is a
paucity of knowledge on the clinical course and outcomes
of asthma in this population [295].
Major findings
In the first cohort of the Rotterdam Study (RS-I) of 7,983
participants, 648 cases have been identified with incident
COPD after a median follow-up time of 11 years, resulting
in an overall incidence rate of 9.2/1,000 person-years (PY)
(95 % CI 8.5–10.0) [296]. The incidence rate of COPD was
higher in smokers than in never-smokers (12.8/1,000 PY;
95 % CI 11.7–13.9 vs. 3.9/1,000 PY; 95 % CI 3.2–4.7) and
higher in men than in women (14.4/1,000 PY; 95 % CI
13.0–16.0 vs. 6.2/1,000 PY; 95 % CI 5.5–7.0). In the
second and third cohort of the Rotterdam Study (RS-II and
RS-III) of 3,011 and 3,932 participants, respectively, a
diagnosis of COPD has been validated in 782 subjects
based on spirometry, files from the general practitioners
and hospital discharge letters.
COPD and comorbidities
Since COPD does not only affect the lungs, but is also
associated with extrathoracic manifestations and comor-
bidities, an important line of research focuses on the
association of COPD with other diseases (such as cardio-
vascular, cerebrovascular, endocrine, oncological and
neurological diseases). COPD has been shown to be an
independent risk factor for ischemic stroke and the risk
increases by severity of airflow limitation. We investigated
the prevalence of carotid artery wall thickening by ultra-
sonography and characterized the carotid artery plaque
composition by high-resolution magnetic resonance imag-
ing in subjects with COPD compared with non-smoking
and smoking subjects without airflow limitation. COPD
subjects had a twofold increased risk of carotid wall
thickening compared with control subjects with a normal
lung function (odds ratio, 2.0; 95 % CI 1.44–2.85), and the
risk increased significantly with severity of airflow limi-
tation [297]. Importantly, vulnerable lipid core plaques
were more frequent on magnetic resonance imaging in
COPD cases than in control subjects (odds ratio, 2.1; 95 %
CI 1.25–3.69). Since vulnerable carotid artery plaques
place persons at risk for ischemic stroke through disruption
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of the plaque surface and thromboembolism, these obser-
vations offer new insights into the link between COPD and
ischemic stroke.
COPD and systemic inflammation
We investigate the role of systemic inflammation in the
pathogenesis of COPD and its comorbidities. Using a
Mendelian randomization approach, we investigated the
role of C-reactive protein (CRP) and interleukin-6 (IL-6) in
the pathogenesis of COPD. We demonstrated that
increased serum levels of high sensitivity (hs) CRP
([3 mg/l), a marker of systemic inflammation, are signif-
icantly associated with an increased incidence of COPD
(hazard ratio (HR), 1.7; 95 % CI 1.16–2.49) compared with
subjects with low CRP levels (\1 mg/l), but that variations
(single nucleotide polymorphisms and haplotypes) in the
CRP gene are not associated with COPD [298]. Since IL-6
induces the expression of acute phase proteins such as CRP
in hepatocytes, we performed a Mendelian randomization
study of IL-6 in the Rotterdam Study. Increased plasma
levels of IL-6 at baseline were significantly associated with
an increased risk to develop COPD [299]. However,
genetic variation in the IL-6 gene did not alter the risk for
COPD. These findings suggest that IL-6 and hsCRP are
markers of systemic inflammation, but are not driving the
pathogenesis of the pulmonary dysfunction in COPD
(makers of disease).
Genetic determinants of lung function and COPD
COPD is an obstructive airway disease, characterized by a
reduced ratio of forced expiratory volume in one second
(FEV1) to forced vital capacity (FVC) (i.e. FEV1/FVC).
The first genome-wide association study (GWAS) of pul-
monary function measures, performed in the Framingham
Heart Study, identified single nucleotide polymorphisms
(SNPs) near the HHIP (hedgehog-interacting protein) gene
on chromosome 4q31 which were associated with the
FEV1/FVC ratio. We meta-analyzed GWAS for FEV1/FVC
in 20,890 participants of European ancestry from four
CHARGE Consortium studies: Atherosclerosis Risk in
Communities, Cardiovascular Health Study, Framingham
Heart Study and Rotterdam Study. We confirmed the HHIP
locus and identified seven novel loci associated with FEV1/
FVC at genome-wide significance [P \ 5 9 10(-8)],
including GPR126 (G-protein-coupled receptor 126),
ADAM19 (A disintegrin and metalloproteinase 19), AGER
(advanced glycation endproducts receptor), FAM13A,
PID1, HTR4 (serotonin receptor 4) and PTCH1 (patched 1,
receptor for HHIP) [300]. Thanks to collaboration between
the CHARGE and Spirometa Consortium, 16 additional
genetic loci have been shown to be associated with lung
function, including MMP15, TGFB2, HDAC4 and RARB
(retinoic acid receptor B) [301]. Since several identified
genes (e.g. RARB, HHIP and PTCH1) play crucial roles in
lung development by regulating branching morphogenesis
during foetal life, the results of these GWAS suggest that
genetic variants associated with lung development and
growth might be important genetic determinants of lung
function in childhood and adulthood, both in healthy sub-
jects and in patients with airway disease (asthma and
COPD) [302].
Since only approximately 20 % of smokers develop
COPD, genetic risk factors are suspected to be involved in
the pathogenesis of the disease. In the Rotterdam Study, we
confirmed the association between the SNPs near the HHIP
gene and COPD, and demonstrated a significant interaction
with the number of pack-years of smoking [303]. In a
collaborative effort of fifteen cohorts, we performed meta-
analyses of GWAS for airflow obstruction, a key patho-
physiologic characteristic of COPD, defined as FEV1 and
FEV1/FVC both less than their respective lower limits of
normal. We confirmed the association of airflow obstruc-
tion to the chromosome 15 CHRNA5/CHRNA3 (nicotinic
acetylcholine receptor, subunits alpha 5 and alpha 3) gene
cluster, even in never smokers, and implicated the HTR4
gene in the pathogenesis of COPD [304]. In gene expres-
sion studies we confirmed the presence of CHRNA5/3 in
lung, bronchial epithelial cells and airway smooth muscle
cells, suggesting that the CHRNA5/3 region might act as a
genetic risk factor for airflow obstruction independent of
smoking. Lastly, in genome-wide joint meta-analyses of
SNP and SNP-by-smoking associations on FEV1 and
FEV1/FVC across 19 studies, we identified three novel loci
not previously associated with pulmonary function. SNPs
in or near DNER, KCNJ2 and SOX9, and the HLA region
(HLA-DQB1 and HLA-DQA2), were associated with FEV1/
FVC or FEV1 [305]. These findings demonstrate that joint
testing of SNP and SNP-by-environment interaction is able
to identify novel loci associated with complex traits that
are missed when considering only the genetic main effects.
Methods update
Lung function measurements
Spirometry is performed by trained paramedical personnel
using an electronic spirometer with pneumotachograph
(Jaeger Master Screen PFT, Cardinal Health, Hoechberg,
Germany), according to the American Thoracic Society
(ATS)/European Respiratory Society (ERS) guidelines.
Forced expiratory volume in one second (FEV1), forced
vital capacity (FVC) and FEV1/FVC ratio are measured.
The spirogram (volume-time curve) and the maximal
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expiratory flow-volume curve are recorded. The spirome-
tries are interpreted by two research physicians according
to the ATS/ERS guidelines; a senior respiratory physician
decides in case of discordance between both physicians.
Diffusing capacity of the lungs (DLCO) is measured by
single-breath determination of carbon monoxide (CO)
uptake in the lung using the Jaeger Master Screen PFT Pro
Diffusion apparatus according to the ATS/ERS task force on
standardization of lung function testing [306]. The test gases
used to calculate DLCO include the tracer gas methane, to
measure alveolar volume (VA), and carbon monoxide (CO
0.3 %). The DLCO and the diffusing capacity for CO per
unit of alveolar volume, also known as transfer coefficient of
the lung (i.e. DLCO/VA or KCO), are corrected for blood
hemoglobin levels, measured at the same visit of the par-
ticipants to the Rotterdam Study center.
Clinical assessment of COPD
For the validation of the COPD cases, we have access to
spirometry reports, files from the general practitioners,
hospital discharge letters and pharmacy dispensing data for
subjects participating in the Rotterdam Study. The diag-
nosis of COPD is based on an obstructive spirometry
examination according to the modified Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria (FEV1/
FVC \ 70 %) and classified into mild, moderate, or severe
airflow limitation by FEV1% predicted of C80 %,
50–80 % or \50 % respectively. Clinical outcomes are
collected during our continuous follow-up and encompass
respiratory and non-respiratory death, hospitalizations due
to exacerbations of COPD (defined as severe exacerba-
tions) and exacerbations of COPD treated with antibiotics
and/or systemic corticosteroids (i.e. moderate exacerba-
tions). In addition, according to the GOLD 2011 update,
the influence of respiratory symptoms is evaluated. Dysp-
noea score is based on five dyspnoea-related questions and
scored from 0 (never dyspnoeic) to 5 (even dyspnoeic at
rest). In addition to the spirometric classification of COPD
severity according to GOLD 2007 (GOLD grade I, II and
III based on mild, moderate and severe airflow limitation),
we also assess COPD subjects according to the updated
classification of GOLD 2011 [292]. COPD cases are clas-
sified as GOLD A, B, C and D according to the combined
assessment of airflow limitation, symptoms and exacerba-
tion history. COPD subjects A have few symptoms and low
risk (spirometric classification: GOLD grade 1–2 and B1
exacerbations per year); COPD subjects B have more
symptoms but low risk; COPD cases C have few symptoms
but high risk (GOLD grade 3–4 as spirometric classifica-
tion or C2 exacerbations per year) and lastly COPD cases
D report more symptoms and have high risk. Chronic
bronchitis is defined as the self-reported presence of cough
and sputum for at least 3 months in each of two consecu-
tive years.
For additional EJE references see [307–324].
Genetic and biomarker studies
Objectives
The team in this research line focusses on bio-banking
activities of the participants of the Rotterdam Study and
investigates biological determinants of disease (i.e., DNA,
RNA, proteins, metabolites). Bio-banking involves col-
lecting, storing and managing the biological tissues of
participants of the Rotterdam Study at all follow-up mea-
surements. This concerns mainly blood and urine but
increasingly also other tissues and bio-materials, such as
sputum, hair and faeces. The research of this group con-
cerns assessment of biological determinants of disease
(biomarkers) in these bio-materials. The analysis of
markers using genomic technologies (using SNP arrays and
next generation sequencing) has substantially increased in
volume and importance over the past years.
Major findings
Rotterdam Study investigators are playing leading roles in
the emerging large global consortia focussed on assessing
the contribution of complex disease gene variants by pro-
spective meta-analysis across many epidemiological
cohorts, such as in CHARGE and ENGAGE, and in many
disease/phenotype focused efforts such as GEFOS, RE-
PROGEN, TREATOA, DIAGRAM, etc. Since 2005 the
genome wide association study (GWAs) has changed the
field of complex genetics, and identified a still growing list
of common variants contributing to disease risk and
explaining genetic variance of traits. While this large scale
global collaboration has originated from the GWAS era, we
now see similar consortia being built around the newer
genomics datasets with RNA expression profiles, DNA
methylation profiles, and the NGS datasets on DNA, RNA
and microbiomes.
The Rotterdam Study has GWAS data for almost the
complete dataset summing to over 12,000 DNA samples,
and is involved as a major collaborative centre for meta-
analysis studies of GWAS data, including national pro-
grams (RIDE, NGI-NCHA), EU-funded projects (GEFOS,
TREATOA, ENGAGE), and voluntary collaborations
(GIANT, MAGIC, CHARGE). Especially, from the
CHARGE consortium (the Rotterdam Study together with
the Framingham Study, AGES, CHS, and ARIC) many
important publications have emerged on a wide variety of
phenotypes and diseases from all major research lines in
The Rotterdam Study 905
123
the Rotterdam Study [325]. You can find them discussed
under the subheadings of each individual research line.
Data collection, storage and management
At each examination at the research centre, blood, serum,
plasma (citrate, heparine, and EDTA based), and sputum
are collected. Fasting blood samples are collected along
with challenged samples as part of a glucose tolerance test.
Sputum is collected before and after a dexamethasone-
suppression test. Sputum is frozen at -196 C before and
after the challenge and stored at -80 C. To obtain serum
and plasma, tubes are centrifuged according to a protocol
standardising time and conditions from the drawing of
blood to centrifugation. All samples are snap frozen at -
196 C using liquid nitrogen and stored at -80 C. Over-
night urine samples are collected at home, frozen at -
196 C at the research centre and stored at -80 C.
DNA is isolated from whole blood at one laboratory at
Erasmus MC by a manual salting-out protocol and is
subsequently stored in Eppendorff tubes at -20 C. A copy
of the complete DNA collection of *13,000 samples has
been transferred to Matrix 2D-barcode tubes in 96 well
format at another location. This copy has been subjected to
normalization of DNA concentrations and made suitable
for handling in 96- and 384-well micro-titer plates for
subsequent downstream genomic analysis.
Starting with the RS-III round of data collection, blood
drawing has also been taken place with PAXgene tubes,
from which whole RNA is isolated and stored at -80 C.
This is now ongoing for the whole study population fol-
lowing the cycles of visits to the research centre.
Similarly, with the RS-III round, collection of faeces
material has been initiated for the intestinal microbiome
analysis. A collection pot is distributed at the research
centre visit which is to be used at home and then by postal
mailed returned to Erasmus MC where DNA is isolated and
stored at -80 C. This is now ongoing for the whole study
population following the cycles of visits to the research
centre.
For data management, an in-house customized sample-
management system has been developed. All genomic data
of the Rotterdam Study (e.g., SNP array, RNA expression,
Next Generation Sequencing (NGS) DNA and RNA, mi-
crobiome NGS) are generated in one laboratory which
keeps all raw data, while QC-ed and extracted data are
stored and managed in the central data repository of the
Rotterdam Study.
Blood serum/plasma assessments
For all participants, serum cholesterol, HDL, LDL, tri-
glycerides, glucose and glucose levels are assessed. In
urine, micro albumin and creatinine are determined in all
participants. Recently, a new ‘‘baseline’’ serum biomarker
dataset has been generated at the Clinical Chemistry Lab-
oratory and the Endocrine Laboratory consisting of RS-I-3,
RS-II-2, and RS-III-1 samples. These measurements
include a steroid profile by mass-spectrometry (e.g.,
estrogens, androgens, vitamin D, cortisol), thyroid hor-
mones (TSH, free T4), interleukins, CRP, IGF1, insulin,
iron-parameters (iron, ferritin and transferrin saturation),
fibrinogen, homocysteine, folic acid, riboflavine, pyridox-
ine, SAM/SAH ratio, cobalamine, Lp-PLA2, Fas/Fas-L,
and abeta42/40.
Human genomics facilities
The Rotterdam Study uses one Erasmus MC laboratory for
all its genomic studies on DNA, RNA, methylation, mi-
crobiome, etc. The facilities use high-end automated
machinery including 2 Caliper pipetting robots (including a
TwisterII, and integrated plate reader (OD 260/280), 2
Tecan EVO 150 Freedom pipetting robots, a Deerac
Equator NS808 nanoliter liquid dispenser, PCR machines,
an ABI7900HT Taqman machine (running 1 ng gDNA in 2
microliter reactions), 2 Illumina iScan micro-array readers,
one Roche 450 GS Junior sequencer, and two Illumina
HiSeq2000 sequencing machines. DNA sample handling is
centred on 384-well plates. Single SNP genotyping studies
are done mostly using Taqman and Sequenom genotyping
with throughputs at 30,000 genotypes per day. We work
with reduced amounts of input genomic DNA of 1 nano-
gram per genotype. This facility has been generating all
GWAS data for the Rotterdam Study as well as its RNA
expression profiles, methylation profiles, and all NGS data
including whole exome sequences, RNA sequencing, and
microbiome sequencing.
Genome-wide association studies (GWAS) datasets
Genome-Wide Association Studies (GWAS) are based on
genotyping epidemiological cohorts with high density
SNP arrays with 500,000—5 million SNPs. The method
has been shown to successfully identify common genetic
factors for hundreds of traits and diseases (see www.
genome.gov/ GWAstudies). Through a large grant from
the Dutch research organisation NWO one of the world’s
largest GWAs datasets has been facilitated involving over
12,000 DNA samples from the Rotterdam Study cohorts.
This GWAS dataset consists of (a) a small dataset of
*450 women with 500 K Affymetrix arrays
(Nsp250 ? Sty250), and (b) a large dataset of *12,000
samples covering almost all RS-I, RS-II, RS-III DNA
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samples consisting of 550 K (RS-I, II; single ? duo array
format) and 610 K (RS-III; quattro array format) Illumina
array genotypes.
The Illumina GWAS dataset of the Rotterdam Study
(with approximately 500,000 SNPs having been geno-
typed) also forms the basis to generate so-called ‘‘imputed’’
datasets derived thereof. In this process the genotypes of
SNPs which have been genotyped in reference datasets
(such as HapMap with *8 million SNPs genotyped), are
being estimated for all Rotterdam Study samples using the
basis Illumina 500 K SNP dataset configurations in each
subject. With the advent of large reference datasets
becoming available based on whole genome/exome NGS,
imputation activities using the Rotterdam GWAS dataset
will remain an active area of development. So far, the
Rotterdam Study GWAS dataset has been imputed to
HapMap version 2 and 3 (with *7.5 million resulting SNP
genotypes in the Rotterdam Study dataset), and the 1000
genome dataset version 4 (with *18 million resulting SNP
genotypes in the Rotterdam Study daaset). Currently,
imputations are being generated for the Genome of the
Netherlands (GoNL) whole genome NGS dataset [326],
and the 10KUK whole genome sequencing dataset.
The Rotterdam Study GWAS dataset is actively being
used by all research lines within the Rotterdam Study as
can be read under the subheadings of each research line in
this review of the Rotterdam Study. In addition, it also
serves as a control GWAS dataset for other research cen-
ters in- and outside The Netherlands for both SNP fre-
quencies as well as copy number variations (CNVs), in
which capacity it has been used in *100 publications up to
date. Most importantly, it has formed the start of a very
successful collaboration in the CHARGE consortium
(combining GWAS datasets of major epidemiological
cohort studies across the world) which has [70 phenotype
working groups in which almost all research lines of the
Rotterdam Study are active.
Candidate gene SNP studies
In the past, we have genotyped over 300 individual poly-
morphisms as part of candidate gene studies across the
complete Rotterdam Study cohort using Taqman and Se-
quenom genotyping techniques. These mostly concern
individual potentially functional single nucleotide poly-
morphisms (SNPs) per gene, but sometimes also haplotype
tagging SNPs (e.g., ESR1, ESR2, HSD11B1, fibrinogen),
and also high density SNP screening (e.g., the vitamin D
receptor gene). Currently, for candidate gene/SNP studies
we perform look-ups in the GWAS datasets and/or perform
individual SNP genotyping (e.g., SNPs not on the array,
badly imputed SNPs, functional SNPs).
RNA expression datasets
With the availability of good RNA from Rotterdam Study
participants, starting with the RS-III subjects, studies have
been initiated analysing the expression pattern of a single
gene across samples or of the complete RNA collection in a
sample (expression profiling). An expression profiling
dataset has now been generated of the first *1,000 samples
of the RS-III dataset, using the Illumina Human HT-12 v4
array containing *48,000 probes. Subsequently, these
same RNA samples are currently being subjected to NGS
(see below) so that a very rich expression dataset will
become available. While RNA expression is known to
differ between tissues, so far we only have RNA isolated
from whole blood as a tissue.
Methylation datasets
In *1,000 samples of the RS-III dataset we have generated
DNA methylation profiles of *480,000 CpG sites across
the human genome using the Illumina Infinium Human-
Methylation450 array. As this same set of RS-III subjects
was also used for the RNA expression profiling, deep
genomic studies can now take place in combination with
GWAS data and NGS data in these *1,000 subjects.
New developments: Next Generation Sequencing
datasets
A major development in genomics studies has been the
introduction in the past few years of high-throughput par-
allel sequencing methods (also known as Next Generation
Sequencing or NGS) which allow DNA (and RNA)
sequencing at unprecedented high speed and low costs.
This development has brought sequencing of whole gen-
omes within reach of individual laboratories, rather than
the large global effort that was needed to sequence the
human genome at first pass. This development has led to a
revival in Mendelian Genetics by solving many ‘‘cold
cases’’ (because causal mutations could directly be found
in a few samples, rather than by linkage analysis in many
family samples and laborious sequencing analyses of
dozens of candidate gene exons in the area). In addition, it
has stimulated the cohort studies that had generated GWAS
datasets in the past 5 years, to generate NGS data in part or
all of their samples to find local/regional variants of interest
and variants that are very rare. While whole genome
sequencing is often seen as the ultimate goal in these
efforts, currently almost all labs turn to Whole Exome
Sequencing (WES) because it is much more cost-effective.
In WES the parts that code for amino acids as part of the
encoded proteins (i.e., the exons) are first captured from the
whole genome by hybridization techniques upon which the
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selected parts (the exons) are then subjected to NGS. WES
costs 5-10 times less euro’s than whole genome sequencing
(so, more samples can be done with the same amount of
money) and generates interpretable findings. (note that for
the vast majority of areas in the human genome we have no
good idea what they signify as opposed to exons that
encode functionally important parts, i.e., the parts that
make up the proteins). A large grant from the NGI-spon-
sored Netherlands Consortium for Healthy Ageing
(NCHA), allowed to generate whole exome NGS data for
*3,000 samples by the Erasmus MC genomics facility on
the Illumina HiSeq2000 sequencing machines. The sam-
ples for this experiment were selected to constitutes a
random sample from the RS-I dataset. These NGS data
have been generated, and the samples are now in the pro-
cess of QC and calling of variants. This process is com-
plicated and no golden standard exists, so these steps take
place together with colleagues at Baylor College, the Broad
Institute, and NGS facilities in Germany and Netherlands.
Through a collaborative grant from the NIH Alzheimer
initiative we will also obtain an additional *2,000 samples
with whole exome NGS data from RS-I. Also here we
collaborate with colleagues in CHARGE since NGS data
have been generated in large parts of the ARIC study, the
Framingham Study, and the CHS study. Within the several
working groups these data are currently being analysed in
relation to specific phenotypes.
From the first NGS efforts in reference datasets using
whole exome sequencing, many thousands of novel DNA
sequence variants were discovered in the exons, mostly
rare to very rare and not well-covered on the existing
GWAS arrays. Illumina and Affymetrix therefore decided
to generate an array devoted to analyse these new exome
variants called the Infinium HumanExome array. This array
has been used to genotype many DNA samples across the
globe and several collaborative analyses are currently using
data generated with this array. In the Rotterdam Study we
generated exome array genotypes of *3,000 samples of
RS-I (with version 1 of this array), and this dataset is part
of several collaborative efforts, including the Dutch
BBMRI exome array effort (with *35,000 collective
samples), an effort in GIANT on anthropometric traits, and
the CHARGE exome array effort across many different
phenotype working groups (with *60,000 collective
samples).
The RNA we have isolated from *1,000 RS-III whole
blood samples is currently being subjected to NGS ana-
lysis. This effort is part of the Dutch BBMRI bio-banking
initiative together with other Dutch biobanks, such as
LifeLines and the Netherlands Twins Register.
We have isolated DNA from faeces of *1,000 RS-III
subjects and this DNA is currently being analysed by 16S
RNA sequencing using the Roche 454 Junior NGS
machine. We are now setting up the protocols to start
running whole DNA sequencing from these samples (called
meta-genomics).
For additional EJE references see [9, 121, 277, 285,
327–349].
Pharmaco-epidemiologic studies
Objective
A major objective of the pharmaco-epidemiologic studies
is to investigate the role of drugs as determinants of disease
in the Rotterdam Study. This includes studying efficacy
and effectiveness of drugs, as well as adverse reactions to
drugs. As the drugs used in the Rotterdam Study are
licensed and often on the market since several years,
research focuses on effect modifiers on the association
between drugs and disease. A topic of particular interest is
pharmacogenetics and genomics as genes may may
account for most of the variation in drug response.
Major findings
Important findings have been published on pharmaco-epi-
demiological topics concerning the main outcomes in the
Rotterdam Study. Subsequently, we will summarize phar-
macogenetic- and other findings.
Pharmacogenetic findings
Pharmacogenetic activities in the Rotterdam Study can be
distinguished into hypothesis-generating ‘genome-wide
association’ (GWA) studies, and in hypothesis-testing
candidate gene studies. As the performance of GWA
studies on gene-drug interactions require a very large
sample size, the Rotterdam Study actively participates in
the CHARGE consortium [350]. This is currently ‘work
under progress’ and up till now most comes from GWA
studies within the Rotterdam Study on specific topics. A
very attractive topic consists of coumarin anticoagulants as
the measurement of anticoagulation through the Interna-
tional Normalized Ratio (INR) is not only a very well
standardized secondary outcome but also in indirect mea-
sure of drug adherence. Interesting were the results of a
GWA in users of the anticoagulant phenprocoumon which
confirmed the important genetic variant for VKORC1,
CYP2C9 and 4F2 in acenocoumarol users [351], and later
also in phenprocoumon dosage [352]. Although 4F2 was a
relatively new finding, further studies on 4F2 revealed that
its contribution was very modest [353]. Another genetic
determinant, i.e. GATA-4, did not have a clinically
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relevant effect on the maintenance dose of acenocoumarol
or phenprocoumon [353]. A recently developed ‘European
Pharmacogenetics of Anticoagulant Therapy (EU-PACT)
acenocoumarol dose algorithm performed as well in the
Rotterdam Study as in the original trial [354]. Two anal-
yses in the Rotterdam Stuy investigated the potential
interaction between coumarin anticoagulants and other
drugs, i.e. antidepressants and proton pump inhibitors. The
risk for overanticoagulation during acenocoumarol main-
tenance treatment was more than doubled in combination
with fluvoxamine and venlafaxine. There was no increase
in risk for the other SSRIs, but numbers of exposed cases
were low for all SSRIs except paroxetine [355]. As for the
potential interaction between proton pump inhibitors and
coumarins, the risk for overanticoagulation was most pro-
nounced for esomeprazole and lansoprazole [356].
A promising subject for pharmacogenetic research
consists of the effect of metformine in diabetics. Previ-
ously, we demonstrated that there were important genetic
variations in OCT1 and MATE1 transporters with conse-
quences for metformine response in diabetics [357–359].
Recently, we participated in a consortium meta-analyis
demonstrating that a gene variant near ATM is significantly
associated with metformin treatment response in type 2
diabetic patients from the Netherlands and the UK [360].
Other interesting study results comprised our finding that
several statins are substrates for the multidrug resistance-
associated protein 2 transporter, encoded by the ABCC2
gene [361], and that the cytochrome P450 CYP1A2
encoding gene variant rs2472299G [A, female sex, and
nonsmoking were significantly inversely related to coffee
intake [362].
Other findings
Electrolyte disorders such as hyponatremia and hypo- and
hyperkalemia are common causes of drug-induced hospital
admissions in the aged. Already since decades and in most
western countries, antihypertensive diuretics are the most
frequent iatrogenic cause of electrolyte disorders [363].
In a cross-sectional analysis in the Rotterdam Study, a
total of 776 subjects (15.0 %) had at least 1 electrolyte
disorder, with hyponatremia (7.7 %) and hypernatremia
(3.4 %) being most common. Diuretics were independently
associated with several electrolyte disorders: thiazide
diuretics (hyponatremia, hypokalemia, hypomagnesemia),
loop diuretics (hypernatremia, hypokalemia), and potas-
sium-sparing diuretics (hyponatremia) [364]. The risk of
hyponatremia was increased eightfold in users of thiazides,
independent of sex and glomerular filtration rate, but not of
age and BMI [365]. Apart from modifying sodium- and
potassium levels, thiazides are known to retain calcium and
may even be protective against hip fracture [366]. In
women, short-term use of loop diuretics was associated
with an increased level of FDP, reflecting increased bone
resorption by osteoclasts [367].
A productive collaboration between pharmaco-epide-
miology and outcome groups in the Rotterdam Study led to
a study on the association between corticosteroids and
open-angle glaucoma [368]. In the past, the suspicion that
corticosteroids may induce glaucoma. Adjusted for age,
sex, high myopia and family history of glaucoma, none of
the classes of steroids were associated with the incidence of
open-angle glaucoma. In this collaboration, two other drug
groups were studied for their association with eye disor-
ders. First, an association has been suggested in the past
that antithrombotics may also induce open-angle glaucoma.
Although there was a significant intra-ocular pressure
(IOP)-lowering effect of anticoagulants of -0.31 mm Hg,
the IOP-lowering effect of anticoagulants disappeared after
additional adjustment for the use of systemic beta-blockers
[369]. Second, Long-term use of statins appears to be
associated with a reduced risk of OAG, independent of the
IOP. These findings are in line with the idea that statins
have neuroprotective properties [370]. Apart from its car-
diovascular indications, more and more epidemiological
data suggest other beneficial effects. Besides biomechani-
cal mechanisms, the pathogenesis of osteoarthritis may
involve inflammation, vascular alterations and dysregula-
tion of lipid metabolism. In the Rotterdam Study, statin use
was associated with more than a 50 % reduction in overall
progression of osteoarthritis of the knee, but not of the hip
[371]. Underlining the suggestion that the protective effect
of statins on mortality is partly explained by an anti-
inflammatory effect, was that long-term statin use
([2 years) was associated with a 39 % decreased risk of
death in COPD patients. Stratified according to the level of
systemic inflammation, long-term statin use was associated
with a 78 % reduced mortality if hsCRP level [3 mg/L,
versus a non significantly 21 % reduced mortality if hsCRP
level B3 mg/L [372].
New developments
Drugs are attractive determinants in clinical epidemiologic
research because they are probably the most important
therapeutic intervention in health care, and the majority of
all marketed drugs have proven biological activity. As a
nice consequence of the availability of complete medica-
tion histories in Dutch health care, the role of drug expo-
sure can be assessed in a detailed way. In the Rotterdam
Study, there is an almost complete coverage of the popu-
lation as of January 1, 1991, thanks to the fact that all
pharmacies which serve the Ommoord district are on one
computer network. This facilitates the use of detailed
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analyses with the drug as a time-varying determinant [373].
Apart from the performance of collaborative GWA studies
on gene-drug interactions, as alluded to above, there are
two interesting methodological developments in the phar-
maco-epidemiological studies in the Rotterdam Study.
First, based on earlier publications on marginal structural
modeling [374], we are currently analyzing the association
between statins and cardiovascular mortality with such
models in which we try to use more precise exposure
definitions than use/non-use. Second, in an effort to
translate pharmacokinetic data from clinical trials to pop-
ulation-based research, PK/PD-modelling was performed
on the association between sotalol and the length of the
QTc-interval on ECGs [375].
For additional EJE references see [128, 376–390].
Imaging studies
Objective
Biomedical imaging allows for non- or minimally-invasive
assessment of structural and functional changes that may
reflect specific pathology. Recent developments in image
data acquisition and analysis enable to use these techniques
on a large scale. The Population Imaging Unit within the
Rotterdam Study aims to assess imaging biomarkers of
disease in a pre-symptomatic phase at the population level.
Advantages of imaging measures include that they mark
early disease, can be assessed reliably and reproducibly,
and are quantitative rather than qualitative which makes
them more powerful than most conventional outcome
measures such as clinical phenotypes.
The main imaging modalities that are currently being
applied in the Population Imaging Unit are multidetector
computed tomography (MDCT) and magnetic resonance
imaging (MRI).
Imaging infrastructure and storage
Mdct
CT imaging is currently performed with hospital-based
16-slice or 64-slice MDCT scanners (SOMATOM Sensa-
tion 16 or 64, Siemens, Forcheim, Germany), located at
Erasmus University Medical Center. Scanners are operated
by clinical technicians. CT images are acquired without
contrast-enhancement and according to standardized pro-
tocols. Imaging data are transferred from the CT scanner to
a securely backed-up research picture archiving system.
Mri
From August 2005 onwards, a dedicated 1.5 Tesla MRI
scanner (GE Healthcare, Milwaukee, Wisconsin, USA) is
operational in the Rotterdam Study research center. This
scanner is operated by trained research technicians and all
imaging data are collected according to standardized
imaging protocols. Changes or updates in hardware or
software configuration are avoided and regular quality
checks are performed to secure validity of cross-subject
and cross-scan comparisons. Imaging is performed without
administration of contrast agents. All imaging data are
directly transferred from the scanner facility to the Erasmus
University Medical Center. Data are stored on a securely
backed-up research picture archiving system, using pro-
grammed scripts to check for completeness of the data
received.
Data management and processing
Assessment of incidental findings
All imaging data are visually evaluated within days after
acquisition by trained physicians for the presence of clin-
ically relevant incidental findings [202]. Expert radiologists
are consulted for all abnormal findings and the manage-
ment of clinically relevant findings is based on protocols
defined by expert panels. These protocols are updated on a
regular basis incorporating the current best available
knowledge regarding treatment and prognosis of the vari-
ous abnormalities discovered.
Automated processing of MRI data
Though some measurements are still performed manually
or scored visually, the majority of imaging data is now
processed using semi- and fully-automated computer
algorithms. The Population Imaging Unit collaborates with
the Biomedical Imaging Group Rotterdam (BIGR) of
Erasmus University Medical Center in the application and
development of automated processing pipelines for high-
throughput of large data quantities. These pipelines com-
prise on the one end image quality checks and procedures
for non-uniformity correction, normalization and image
registration and on the other end advanced algorithms to
extract image features to use for analyses.
Grid architectures and networked processing pipelines
are used to process the large quantities or imaging data that
are acquired in the Rotterdam Study.
910 A. Hofman et al.
123
Major findings
The Rotterdam Study research lines currently applying
imaging within the Population Imaging Unit are those on
neurological diseases and cardiovascular diseases.
Brain imaging (MRI)
Neurodegenerative and cerebrovascular disease are com-
mon disorders in the elderly that exert a large influence on
brain functioning. Identifying underlying pathology in a
preclinical state may help to recognize persons at risk,
assess determinants of disease and develop preventive
measures. Main objective for the Population Imaging Unit
with respect to brain imaging is therefore to identify and
quantify brain imaging biomarkers that mark the develop-
ment of neurodegenerative and cerebrovascular disease.
From August 2005 onwards (RS-II-2 and onwards),
brain imaging in the Population Imaging Unit is performed
in all study participants without contra-indications in the
context of the Rotterdam Scan Study. The current structural
scanning protocol includes 4 high-resolution axial
sequences (3D T1-weighted; 2D PD-weighted; 2D FLAIR;
and 3D T2* GRE), 2D phase-contrast imaging, and diffu-
sion tensor imaging (DTI). Total scanning time for these
sequences amounts to approximately 30 min. Currently,
over 5,700 unique brain MRI scans and over 4,800 follow
up scans have been acquired with this protocol. Starting
2012, functional imaging is incoporated in the MRI pro-
tocol in the form of a resting-state fMRI sequence (8 min),
which is added to the existing structural scans. To date, rs-
fMRI scans have been acquired in approximately 1,000
individuals and this will continue into 2014.
Fully automated methods are applied to quantify atrophy of
brain tissues and structures and the severity of white matter
lesions [218, 391, 392]. Automated hippocampal segmenta-
tion has been successfully applied on multi-scanner acquired
MR images (on scans acquired in the Rotterdam Scan Study in
1995 [211] and follow up examinations in 2006), showing that
a decline in hippocampal volume over a 10-year follow up
period predicted onset of clinical dementia [393]. Apart from
focusing only on supratentorial brain structures, we have more
recently also incorporated segmentation of the cerebellar
volume into our automated processing pipelines, enabling us
to study the cerebellum in aging. In 3,962 persons, we found
that smaller cerebellar volumes with increasing age were
mainly driven by loss of white matter. Furtermore, diabetes,
higher serum glucose and lower cholesterol levels were most
important risk factors for cerebellar atrophy in aging.
Phase-contrast imaging allows for assessment of blood
flow in the carotids and basilar artery. This yields measures
of total brain perfusion [394], which when lower was found
to be relate to worse cognition, an association that is
mediated by brain atrophy [395].
The 3D T2* GRE sequence that we use was specifically
developed to increase the conspicuity of cerebral micro-
bleeds [396]. With this optimized sequence, we found that
microbleed prevalence gradually increases with age, from
6.5 % in persons aged 45 to 50 years to 35.7 % in partic-
ipants of 80 years and older; and that overall, 15.3 % of all
subjects over the age of 45 years has at least 1 microbleed;
a much higher prevalence than was reported before [370,
371]. We found supportive evidence that deep or infra-
tentorial microbleeds reflect arteriolosclerotic angiopathy,
whereas strictly lobar microbleeds are caused by cerebral
amyloid angiopathy [397, 398]. We furthermore demon-
strated that incidence of microbleeds over a 3-year time
interval is high and that risk factors for new microbleeds
again differ according to microbleed location, in line with
our findings regarding prevalent microbleeds [399]. These
findings impact research into the causes of cerebral amy-
loid angiopathy, as well as fuel the ongoing discussion
about the safety of antithrombotic therapy in persons with
microbleeds [400, 401]. Our current studies focus on the
clinical relevance of cerebral microbleeds, in relation to
clinical outcomes such as stroke, dementia and mortality,
over a mean follow-up of 5 years.
Diffusion tensor imaging (DTI) allows the assessment of
the microstructural integrity of white matter. White matter
microstructure looses its integrity with increasing age, but
this can largely be explained by presence of white matter
atrophy and white matter lesions [402].
Nevertheless, the microstructural integrity in the normal
appearing white matter and in white matter lesions relates
to cognitive function regardless of concurrent macrostruc-
tural changes, emphasizing the importance of the micro-
structural integrity of white matter [403]. Also, we found
that white matter changes in normal appearing white matter
are present and can be quantified on diffusion tensor
imaging before white matter lesions actually develop. This
suggests that white matter lesions develop gradually, and
that visually appreciable lesions are only the tip of the
iceberg of white matter pathology. We recently developed
within the Rotterdam Study a method for fully automated
tractography of over 20 major white matter tracts, yielding
tract-specific measures of white matter integrity, enabling a
more in-depth exploration of structural integrity in relation
to functional processes in aging [404].
Imaging of atherosclerotic calcifications (MDCT)
Main objectives with respect to imaging of vascular cal-
cifications are to investigate distribution of and risk factors
for atherosclerotic calcifications in the general elderly
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population and to study prognosis associated with calcifi-
cations in different vessel beds.
From September 2003 until February 2006, all partici-
pants from RS-I-4 and RS-II-2 who completed a center
visit were invited to a MDCT scan of the coronary arteries
and a second scan of the aortic arch and carotid arteries. A
total of 2,521 participants (response rate 79 %) were
scanned. The cardiac scan reached from the apex of the
heart to the tracheal bifurcation. The second scan reached
from the aortic arch to the intracranial circulation. Images
were analyzed by trained reviewers and calcification in the
different vessel beds (coronaries, aortic arch, extracranial
and intracranial carotids) were quantified using the Agat-
ston score [405].
As expected, we found that calcification load was higher
overall in men compared to women, though aortic arch
calcification was more prevalent among women [406]. Age
and current smoking were found to be the strongest inde-
pendent risk factors for arterial calcification [407]. Fur-
thermore, strong and graded associations of prevalent
stroke were found with carotid artery, aortic arch and
coronary artery calcification, independent of cardiovascular
risk factors [408]. When vessel calcification was studied in
relation to vascular brain disease (non-invasively imaged
with MRI), we found that larger intracranial carotid cal-
cification load related to larger white matter lesion load,
and that larger extracranial carotid calcification load rela-
ted to the presence of cerebral infarcts, independently of
ultrasound carotid plaque score. This suggests that calci-
fication of atherosclerotic plaque yields other information
in addition to merely the presence of plaques. This
importance of vessel calcification is further corroborated
by our recent finding that larger calcification volumes are
associated with worse cognitive performance in the general
population.
Despite extensive research on the identification of life-
style- and environmental cardiovascular risk factors, a
large part of the variability in the total burden of athero-
sclerosis remains yet unexplained. This inevitably indicates
that other, unknown factors also considerably contribute to
the development of atherosclerosis. During the last years, it
has become clear that genetic factors may play an impor-
tant role in the development of atherosclerosis. We deter-
mined whether previously identified genetic loci for
coronary calcification were also associated with calcifica-
tion in other locations than the coronary arteries Indeed, we
found that the genetic basis for aortic arch and carotid
artery calcification largely overlaps with that of coronary
artery calcification. However, we found that the genetic
variants contributed differentially to the amount of ath-
erosclerotic calcification in these vessel beds. This suggests
that also on the genetic level, differences in the etiology of
atherosclerosis across vessel beds exist. Additionally, we
also investigated the genetic basis of atherosclerosis using
the genetics of strong risk factors of atherosclerosis, i.e.
serum cholesterol levels and blood pressure and demon-
strated that both serum lipids and blood pressure share a
genetic predisposition with the formation of atherosclerosis
in multiple vessel beds. Worldwide, intracranial athero-
sclerosis is one of the leading causes of stroke, yet it is
understudied in population of white descent. We therefore
focused specifically on the prevalence and risk factors of
intracranial internal carotid artery calcification in our
population, and found that the overall prevalence of
intracranial atherosclerosis was as high as 82.2 %. Con-
ventional cardiovascular risk factors are associated with
intracranial atherosclerosis, but risk factor profiles differed
between men and women, with excessive alcohol intake
and smoking were strong risk factors in men, whereas
diabetes and hypertension were in women. Our current
studies focus on long-term risk of disease associated with
calcifications in various vessel beds, again with a particular
focus on intracranial atherosclerosis.
Carotid plaque imaging (MRI)
Carotid wall thickening and atherosclerosis are highly
prevalent at older age and are considered a major cause of
cerebrovascular events [197]. Carotid atherosclerotic pla-
que constituents such as lipid core and hemorrhage, so-
called ‘‘vulnerable’’ components, are considered important
factors in development of clinical neurological events
[409]. With MRI, it is possible to separately identify these
plaque components [410]. Main objectives with respect to
carotid imaging in the Rotterdam Study are to investigate
distribution of and risk factors for carotid plaque compo-
nents in the general elderly population and to study prog-
nosis associated with specific carotid plaque composition.
From October 2007 onwards, all participants with car-
otid wall thickening of 2.5 mm or larger on ultrasound
(approximately 25 % of the Rotterdam Study population)
are invited for carotid MRI. Imaging is performed with a
bilateral phased-array surface coil (Machnet, Eelde, The
Netherlands), stabilizing subjects in a custom-designed
head holder to reduce motion. The imaging protocol con-
sists of a series of high-resolution MRI sequences to image
the carotid bifurcations on both sides: a PDw Fast Spin
Echo (FSE) Black-blood (BB) sequence; a PDw-FSE-BB
with an increased in-plane resolution; a PDw- Echo Planar
Imaging (EPI) sequence and a T2w-EPI sequence; and 2
three-dimensional (3D) sequences: a 3D-T1w-Gradient
Echo (GRE) sequence; and a 3D phased-contrast MR-
Angiography. Total scanning time amounts to approxi-
mately 30 min.
Plaques are reviewed by trained raters for the presence
of three different plaque components (calcification,
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hemorrhage and lipid core). Furthermore, carotid plaque
size is quantified by obtaining maximum carotid wall
thickness and degree of luminal stenosis using the NAS-
CET criteria [411] on the PDw-FSE images. Postprocess-
ing techniques aimed at automated quantification of plaque
volume and identification of different plaque components
are currently being developed.
So far, over 1,300 participants underwent a complete
carotid MRI scan and data are currently being analyzed.
There is a complete overlap between carotid and brain MRI
participants, allowing for the investigation of carotid pla-
que constituents in relation to brain imaging markers. In
the first 1,006 scans, we found that intraplaque haemor-
rhage and lipid core were present in almost 25 % of pla-
ques, respectively, and occurred simultaneously in 9 % of
plaques. Different risk factors are associated with these
plaque components: hypertension (and in particular high
pulse pressure) and current smoking were risk factors for
the presence of intraplaque haemorrhage, and hypercho-
lesterolaemia was the only risk factor for lipid core
presence.
New developments
As also mentioned above, focus has shifted from purely
structural imaging to also including functional imaging
data, by incorporating resting-state functional MRI into the
brain imaging protocol. Changes in the intrinsic activity of
resting-state networks are presumed to represent alterations
in functional brain connectivity and may mark neurode-
generation in an early, presymptomatic stage. Our initial
studies will focus on the relation between functional brain
connectivity and established structural markers in age-
related brain diseases such as hippocampal volume, white
matter lesions and microbleeds. In a later stage, we will
investigate whether functional connectivity can be used an
early imaging marker for dementia, by itself or in combi-
nation with other imaging markers and risk factors.
Regarding structural imaging markers, an emerging
potential marker is Virchow–Robin (VR) spaces, spaces
filled with interstitial fluid that surround the blood vessels
in the brain and which can be dilated. Despite increasing
literature on these dilated VR spaces, a major limitation of
current research is the lack of a robust and generalizable
rating method on MRI. We recently developed a novel
rating method for VR spaces, which we successfully
applied in 2 population-based studies, encompassing 3
different scanning protocols. We will use this rating
method to explore determinants and consequences of
dilated VR spaces in our general aging population.
Besides ever-increasing advances in imaging hardware,
software and sequence design, major advances in the short
and long run are to be expected from (fully) automated
image analysis. Computer processing of images will enable
to make fully use of all information contained within the
image, introducing new imaging biomarkers. Besides, the
vast amount of imaging data that are acquired in popula-
tion-based studies like the Rotterdam Study renders visual
assessment or manual measurements virtually impossible,
strengthening the need for (fully) automated methods of
data extraction and analysis.
For additional EJE references see [17, 208, 412–415].
Otolaryngological diseases
Objectives
Otolaryngological research in the Rotterdam study focuses
on the frequency, etiology and consequences of auditory
and vestibular disorders. We are mainly interested in dys-
functions located in the labyrinth of the inner ear, expres-
sed by cochlear hearing loss and a deviant vestibulo-ocular
reflex (VOR) for fast head movements. Etiology of both
peripheral disorders will be studied, possibly revealing one
or more common risk factors as both systems are connected
and have similar sensory mechanisms. Additionally, we
will investigate possible associations between reduced
sensory input and general neuroepidemiological measures.
Methods
From 2011 we started measuring hearing and vestibular
function within the Rotterdam Study population. Hearing
loss is assessed at both ears by performing pure-tone
audiometry in a sound proof room. Hearing thresholds are
determined with headphones at frequencies 0.25, 0.5, 1, 2,
4 and 8 kHz. To distinguish between cochlear and middle-
ear pathology, also bone-conduction thresholds are mea-
sured at frequencies 0,5 and 4 kHz. Additionally, speech
perception in noise is tested at the better ear, using a val-
idated triplet digit test [416] with speech-shaped noise at a
fixed presentation level of 65 dB SPL. The ability to
understand speech in noise is a functional measure that
includes both sensory and central aspects of the auditory
system.
Peripheral vestibular function is assessed by The Head
Impulse Test (HIT), which measures the vestibule-ocular
reflex (VOR) for a number of sudden head movements
initiated by the tester [417]. Gain and delay are the main
parameters that will be used to quantify vestibular function.
An advanced infrared video-oculography system is used to
track the eye movements simultaneously with the position
of the head, enabling VOR recordings, even for fast head
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movements. Additionally, central vestibular processing is
assessed by measuring the VOR during repetitive slow
head movements at frequencies 0.5, 1 and 2 Hz while
fixating the eyes at a projected visual target. The oculo-
motor function is tested by eye tracking of a moving target
at frequencies 0.5, 1 and 2 Hz, while the head is fixated.
The general interview contains ten questions related to
hearing and balance problems. In case of hearing-aid use,
the participant has to answer five additional questions of
the International Outcome Inventory of Hearing Aids (IOI-
HA) [418]. In case of frequent tinnitus, ten additional
questions of the Short Tinnitus Handicap Inventory (THI-
S) are added [419].
Determinants of interest
One of our main goals is to find medical and genetic factors
that are associated to age-related hearing loss. Age-related
hearing loss is a common disorder that deprives older
people of key sensory input. It leads to social withdrawal
and is even been found to be independently associated with
poorer cognitive functioning and incident dementia. Still,
little is known about the mechanisms that are responsible
for developing hearing loss and the way it affects general
cognitive functions within the elderly population. Deter-
minants of interest are genetic factors, cardiovascular dis-
ease, use of medication, endocrine diseases and
neuroepidemiological factors.
Even less is known about age-related vestibular dys-
function. Problems related to balance and dizziness are
frequently reported in elderly people, but not much is
known about the prevalence and type of vestibular dys-
function that may cause these problems. This will be the
first large cohort study in which vestibular function will be
measured. The same determinants as mentioned for hearing
will be studied for the vestibular system. Additionally, the
relation between hearing and peripheral vestibular function
will be extensively investigated.
Management
The Rotterdam Study is directed by a Management Team
comprising the scientific principal investigators Sarwa
Darwish Murad (PI Hepatic diseases), Cornelia van Duijn
(PI Genetic epidemiologic studies), Oscar Franco (PI
Cardiovascular diseases and ErasmusAGE), Andre´ Goed-
egebure (PI Otolaryngological diseases), Albert Hofman
(chairman, PI Rotterdam Study), Arfan Ikram (PI Neuro-
logical diseases), Caroline Klaver (PI Ophthalmic dis-
eases), Tamar Nijsten (PI Dermatological diseases), Robin
Peeters (PI Internal Medicine), Bruno Stricker (PI Phar-
maco-epidemiology), Henning Tiemeier (PI Psychiatric
diseases), Andre´ Uitterlinden (PI Genomic studies), and
Meike Vernooij (PI Population Imaging); and Jan Heerin-
ga, MD, PhD, study coordinator, Eric Neeleman, head IT,
and Frank van Rooij, MSc, head data-management. The
study of respiratory diseases is conducted in close collab-
oration with Prof Guy Brusselle, Department of Respira-
tory Medicine, Ghent University Hospital, Ghent, Belgium.
The study of pulmonary hypertension is conducted in close
collaboration with Ardeshir Ghofrani, University of Gies-
sen Lung Center, Giessen, Germany.
Emeritus principal investigators
The following persons are Principal Investigator Emeritus
of the Rotterdam Study:
Frank van den Ouweland (PI Internal Medicine
1990–1992), Diederick Grobbee (PI Cardiovascular diseases
1990–1996), Albert Hofman (PI Neurological diseases
1990–1996), Paulus de Jong (PI Ophthalmic diseases
1990–2005), Huibert Pols (PI Internal Medicine 1993–2006),
Monique Breteler (PI Neurological diseases 1997–2010),
Gabriel Krestin (PI Population Imaging 1998–2010), Johan-
nes Vingerling (PI Ophthalmic diseases 2005–2010), Jac-
queline Witteman (PI Cardiovascular diseases 1997–2011),
Ernst Kuipers (PI Internal Medicine 2007–2013), Harry
Janssen (PI Hepatic diseases 2007–2013).
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